| Year |
Citation |
Score |
| 2023 |
Llibre-Guerra JJ, Iaccarino L, Coble D, Edwards L, Li Y, McDade E, Strom A, Gordon B, Mundada N, Schindler SE, Tsoy E, Ma Y, Lu R, Fagan AM, Benzinger TLS, ... ... Farlow MR, et al. Longitudinal clinical, cognitive and biomarker profiles in dominantly inherited versus sporadic early-onset Alzheimer's disease. Brain Communications. 5: fcad280. PMID 37942088 DOI: 10.1093/braincomms/fcad280 |
0.334 |
|
| 2023 |
Johnson ECB, Bian S, Haque RU, Carter EK, Watson CM, Gordon BA, Ping L, Duong DM, Epstein MP, McDade E, Barthélemy NR, Karch CM, Xiong C, Cruchaga C, Perrin RJ, ... ... Farlow M, et al. Cerebrospinal fluid proteomics define the natural history of autosomal dominant Alzheimer's disease. Nature Medicine. PMID 37550416 DOI: 10.1038/s41591-023-02476-4 |
0.312 |
|
| 2023 |
Swinford CG, Risacher SL, Vosmeier A, Deardorff R, Chumin EJ, Dzemidzic M, Wu YC, Gao S, McDonald BC, Yoder KK, Unverzagt FW, Wang S, Farlow MR, Brosch JR, Clark DG, et al. Amyloid and tau pathology are associated with cerebral blood flow in a mixed sample of nondemented older adults with and without vascular risk factors for Alzheimer's disease. Neurobiology of Aging. 130: 103-113. PMID 37499587 DOI: 10.1016/j.neurobiolaging.2023.06.014 |
0.309 |
|
| 2023 |
Schultz SA, Shirzadi Z, Schultz AP, Liu L, Fitzpatrick CD, McDade E, Barthelemy NR, Renton A, Esposito B, Joseph-Mathurin N, Cruchaga C, Chen CD, Goate A, Allegri RF, Benzinger TLS, ... ... Farlow MR, et al. Location of pathogenic variants in PSEN1 impacts progression of cognitive, clinical, and neurodegenerative measures in autosomal-dominant Alzheimer's disease. Aging Cell. e13871. PMID 37291760 DOI: 10.1111/acel.13871 |
0.312 |
|
| 2023 |
Merrihew GE, Park J, Plubell D, Searle BC, Keene CD, Larson EB, Bateman R, Perrin RJ, Chhatwal JP, Farlow MR, McLean CA, Ghetti B, Newell KL, Frosch MP, Montine TJ, et al. A peptide-centric quantitative proteomics dataset for the phenotypic assessment of Alzheimer's disease. Scientific Data. 10: 206. PMID 37059743 DOI: 10.1038/s41597-023-02057-7 |
0.318 |
|
| 2022 |
Chatterjee P, Vermunt L, Gordon BA, Pedrini S, Boonkamp L, Armstrong NJ, Xiong C, Singh AK, Li Y, Sohrabi HR, Taddei K, Molloy M, Benzinger TLS, Morris JC, Karch C, ... ... Farlow M, et al. Plasma glial fibrillary acidic protein in autosomal dominant Alzheimer's disease: Associations with Aβ-PET, neurodegeneration, and cognition. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 36576155 DOI: 10.1002/alz.12879 |
0.325 |
|
| 2022 |
Ali M, Sung YJ, Wang F, Fernández MV, Morris JC, Fagan AM, Blennow K, Zetterberg H, Heslegrave A, Johansson PM, Svensson J, Nellgård B, Lleó A, Alcolea D, Clarimon J, ... ... Farlow MR, et al. Leveraging large multi-center cohorts of Alzheimer disease endophenotypes to understand the role of Klotho heterozygosity on disease risk. Plos One. 17: e0267298. PMID 35617280 DOI: 10.1371/journal.pone.0267298 |
0.308 |
|
| 2022 |
Morris JC, Weiner M, Xiong C, Beckett L, Coble D, Saito N, Aisen PS, Allegri R, Benzinger TLS, Berman SB, Cairns NJ, Carrillo MC, Chui HC, Chhatwal JP, Cruchaga C, ... ... Farlow M, et al. Autosomal dominant and sporadic late onset Alzheimer disease share a common in vivo pathophysiology. Brain : a Journal of Neurology. PMID 35580594 DOI: 10.1093/brain/awac181 |
0.365 |
|
| 2022 |
Shahid SS, Wen Q, Risacher SL, Farlow MR, Unverzagt FW, Apostolova LG, Foroud TM, Zetterberg H, Blennow K, Saykina AJ, Wu YC. Hippocampal-subfield microstructures and their relation to plasma biomarkers in Alzheimer's disease. Brain : a Journal of Neurology. PMID 35411392 DOI: 10.1093/brain/awac138 |
0.301 |
|
| 2021 |
Salloway S, Farlow M, McDade E, Clifford DB, Wang G, Llibre-Guerra JJ, Hitchcock JM, Mills SL, Santacruz AM, Aschenbrenner AJ, Hassenstab J, Benzinger TLS, Gordon BA, Fagan AM, Coalier KA, et al. A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease. Nature Medicine. PMID 34155411 DOI: 10.1038/s41591-021-01369-8 |
0.307 |
|
| 2021 |
Pichet Binette A, Theaud G, Rheault F, Roy M, Collins DL, Levin J, Mori H, Lee JH, Farlow MR, Schofield P, Chhatwal JP, Masters CL, Benzinger T, Morris J, Bateman R, et al. Bundle-specific associations between white matter microstructure and Aβ and tau pathology in preclinical Alzheimer's disease. Elife. 10. PMID 33983116 DOI: 10.7554/eLife.62929 |
0.31 |
|
| 2020 |
Henderson ST, Morimoto BH, Cummings JL, Farlow MR, Walker J. A Placebo-Controlled, Parallel Group, Randomized Clinical Trial of AC-1204 in Mild-to-Moderate Alzheimer's Disease. Journal of Alzheimer's Disease : Jad. PMID 32310169 DOI: 10.3233/Jad-191302 |
0.425 |
|
| 2020 |
Risacher SL, WuDunn D, Tallman EF, West JD, Gao S, Farlow MR, Brosch JR, Apostolova LG, Saykin AJ. Visual contrast sensitivity is associated with the presence of cerebral amyloid and tau deposition. Brain Communications. 2: fcaa019. PMID 32309804 DOI: 10.1093/braincomms/fcaa019 |
0.3 |
|
| 2020 |
Castillo-Barnes D, Su L, Ramírez J, Salas-Gonzalez D, Martinez-Murcia FJ, Illan IA, Segovia F, Ortiz A, Cruchaga C, Farlow MR, Xiong C, Graff-Radford NR, Schofield PR, Masters CL, Salloway S, et al. Autosomal Dominantly Inherited Alzheimer Disease: Analysis of genetic subgroups by Machine Learning. An International Journal On Information Fusion. 58: 153-167. PMID 32284705 DOI: 10.1016/J.Inffus.2020.01.001 |
0.368 |
|
| 2020 |
Aschenbrenner AJ, James BD, McDade E, Wang G, Lim YY, Benzinger TLS, Cruchaga C, Goate A, Xiong C, Perrin R, Buckles V, Allegri R, Berman SB, Chhatwal JP, Fagan A, ... Farlow M, et al. Awareness of genetic risk in the Dominantly Inherited Alzheimer Network (DIAN). Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 16: 219-228. PMID 31914221 DOI: 10.1002/Alz.12010 |
0.355 |
|
| 2019 |
Wen Q, Mustafi SM, Li J, Risacher SL, Tallman E, Brown SA, West JD, Harezlak J, Farlow MR, Unverzagt FW, Gao S, Apostolova LG, Saykin AJ, Wu YC. White matter alterations in early-stage Alzheimer's disease: A tract-specific study. Alzheimer's & Dementia (Amsterdam, Netherlands). 11: 576-587. PMID 31467968 DOI: 10.1016/J.Dadm.2019.06.003 |
0.342 |
|
| 2019 |
Vöglein J, Paumier K, Jucker M, Preische O, McDade E, Hassenstab J, Benzinger TL, Noble JM, Berman SB, Graff-Radford NR, Ghetti B, Farlow MR, Chhatwal J, Salloway S, Xiong C, et al. Clinical, pathophysiological and genetic features of motor symptoms in autosomal dominant Alzheimer's disease. Brain : a Journal of Neurology. PMID 30897203 DOI: 10.1093/Brain/Awz050 |
0.389 |
|
| 2019 |
Contreras JA, Avena-Koenigsberger A, Risacher SL, West JD, Tallman E, McDonald BC, Farlow MR, Apostolova LG, Goñi J, Dzemidzic M, Wu YC, Kessler D, Jeub L, Fortunato S, Saykin AJ, et al. Resting state network modularity along the prodromal late onset Alzheimer's disease continuum. Neuroimage. Clinical. 22: 101687. PMID 30710872 DOI: 10.1016/J.Nicl.2019.101687 |
0.357 |
|
| 2019 |
Swinford CG, Risacher SL, West JD, Apostolova LG, Wu Y, Farlow MR, Brosch JR, Unverzagt FW, Tallman EF, Deardorff R, Kamer AP, Saykin AJ. P1-405: REGIONAL ASSOCIATION OF CEREBRAL BLOOD FLOW WITH AMYLOID AND TAU IN ALZHEIMER'S DISEASE Alzheimer's & Dementia. 15: P414-P414. DOI: 10.1016/J.Jalz.2019.06.1010 |
0.382 |
|
| 2018 |
Farlow MR, Thompson RE, Wei LJ, Tuchman AJ, Grenier E, Crockford D, Wilke S, Benison J, Alkon DL. A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Assessing Safety, Tolerability, and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease. Journal of Alzheimer's Disease : Jad. PMID 30530975 DOI: 10.3233/Jad-180759 |
0.357 |
|
| 2018 |
Risacher SL, Farlow MR, Bateman DR, Epperson F, Tallman EF, Richardson R, Murrell JR, Unverzagt FW, Apostolova LG, Bonnin JM, Ghetti B, Saykin AJ. Detection of tau in Gerstmann-Sträussler-Scheinker disease (PRNP F198S) by [F]Flortaucipir PET. Acta Neuropathologica Communications. 6: 114. PMID 30373672 DOI: 10.1186/S40478-018-0608-Z |
0.329 |
|
| 2018 |
McDade E, Wang G, Gordon BA, Hassenstab J, Benzinger TLS, Buckles V, Fagan AM, Holtzman DM, Cairns NJ, Goate AM, Marcus DS, Morris JC, Paumier K, Xiong C, Allegri R, ... ... Farlow M, et al. Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease. Neurology. PMID 30217935 DOI: 10.1212/Wnl.0000000000006277 |
0.429 |
|
| 2018 |
Lim YY, Hassenstab J, Goate A, Fagan AM, Benzinger TLS, Cruchaga C, McDade E, Chhatwal J, Levin J, Farlow MR, Graff-Radford NR, Laske C, Masters CL, Salloway S, Schofield P, et al. Effect of BDNFVal66Met on disease markers in dominantly inherited AD. Annals of Neurology. PMID 30014553 DOI: 10.1002/Ana.25299 |
0.409 |
|
| 2018 |
Voss T, Li J, Cummings J, Farlow M, Assaid C, Froman S, Leibensperger H, Snow-Adami L, McMahon KB, Egan M, Michelson D. Randomized, controlled, proof-of-concept trial of MK-7622 in Alzheimer's disease. Alzheimer's & Dementia (New York, N. Y.). 4: 173-181. PMID 29955661 DOI: 10.1016/J.Trci.2018.03.004 |
0.413 |
|
| 2018 |
Hampel H, Mesulam MM, Cuello AC, Farlow MR, Giacobini E, Grossberg GT, Khachaturian AS, Vergallo A, Cavedo E, Snyder PJ, Khachaturian ZS. The cholinergic system in the pathophysiology and treatment of Alzheimer's disease. Brain : a Journal of Neurology. PMID 29850777 DOI: 10.1093/Brain/Awy132 |
0.332 |
|
| 2018 |
Farlow MR. Treatment developments in Alzheimer's disease European Neurological Review. 14: 17-18. DOI: 10.17925/Usn.2018.14.1.17 |
0.405 |
|
| 2018 |
Elsaid NMH, Wen Q, Mustafi SM, Risacher SL, Farlow MR, Apostolova LG, Saykin AJ, Harezlak J, Wu Y. Ic-P-157: Alterations In White-Matter Diffusion Metrics In Preclinical Alzheimer'S Disease: A Subject-Specific Analysis Alzheimers & Dementia. 14. DOI: 10.1016/j.jalz.2018.06.2224 |
0.35 |
|
| 2017 |
Vandenberghe R, Riviere ME, Caputo A, Sovago J, Maguire RP, Farlow M, Marotta G, Sanchez-Valle R, Scheltens P, Ryan JM, Graf A. Active Aβ immunotherapy CAD106 in Alzheimer's disease: A phase 2b study. Alzheimer's & Dementia (New York, N. Y.). 3: 10-22. PMID 29067316 DOI: 10.1016/J.Trci.2016.12.003 |
0.424 |
|
| 2017 |
Hampel H, Mesulam MM, Cuello AC, Khachaturian AS, Farlow MR, Snyder PJ, Giacobini E, Khachaturian ZS. Revisiting the cholinergic hypothesis in Alzheimer's disease: Emerging evidence from translational and clinical research. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 29028480 DOI: 10.1016/J.Jalz.2017.08.016 |
0.427 |
|
| 2017 |
Kinnunen KM, Cash DM, Poole T, Frost C, Benzinger TLS, Ahsan RL, Leung KK, Cardoso MJ, Modat M, Malone IB, Morris JC, Bateman RJ, Marcus DS, Goate A, Salloway S, ... ... Farlow MR, et al. Presymptomatic atrophy in autosomal dominant Alzheimer's disease: A serial MRI study. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 28738187 DOI: 10.1016/J.Jalz.2017.06.2268 |
0.411 |
|
| 2017 |
Sims R, van der Lee SJ, Naj AC, Bellenguez C, Badarinarayan N, Jakobsdottir J, Kunkle BW, Boland A, Raybould R, Bis JC, Martin ER, Grenier-Boley B, Heilmann-Heimbach S, Chouraki V, Kuzma AB, ... ... Farlow MR, et al. Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nature Genetics. PMID 28714976 DOI: 10.1038/Ng.3916 |
0.366 |
|
| 2017 |
Johns BT, Taler V, Pisoni DB, Farlow MR, Hake AM, Kareken DA, Unverzagt FW, Jones MN. Cognitive Modeling as an Interface Between Brain and Behavior: Measuring the Semantic Decline in Mild Cognitive Impairment. Canadian Journal of Experimental Psychology = Revue Canadienne De Psychologie Experimentale. PMID 28481569 DOI: 10.1037/Cep0000132 |
0.346 |
|
| 2017 |
Contreras JA, Goñi J, Risacher SL, Amico E, Yoder K, Dzemidzic M, West JD, McDonald BC, Farlow MR, Sporns O, Saykin AJ. Cognitive complaints in older adults at risk for Alzheimer's disease are associated with altered resting-state networks. Alzheimer's & Dementia (Amsterdam, Netherlands). 6: 40-49. PMID 28149942 DOI: 10.1016/J.Dadm.2016.12.004 |
0.378 |
|
| 2017 |
Chase TN, Farlow MR, Clarence-Smith K. Donepezil Plus Solifenacin (CPC-201) Treatment for Alzheimer's Disease. Neurotherapeutics : the Journal of the American Society For Experimental Neurotherapeutics. PMID 28138837 DOI: 10.1007/S13311-016-0511-X |
0.358 |
|
| 2017 |
Farlow MR, Burns JM, Gorelick KJ, Crockford DR, Grenier E, Wilke S, Cooper EC, Alkon DL. BRYOSTATIN-1 IMPROVES COGNITION AND DAILY LIVING TASKS IN MODERATE TO SEVERE ALZHEIMER’S DISEASE: PRELIMINARY REPORT OF A PHASE 2 STUDY Alzheimer's & Dementia. 13: P1476. DOI: 10.1016/J.Jalz.2017.08.006 |
0.333 |
|
| 2017 |
McDade E, Wang G, Benzinger TL, Buckles VD, Fagan AM, Gordon BA, Hassenstab J, Holtzman DM, Cairns NJ, Goate AM, Marcus DS, Morris JC, Paumier KL, Xiong C, Ricardo A, ... ... Farlow MR, et al. LONGITUDINAL BIOMARKER CHANGES IN AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE FROM THE DIAN STUDY Alzheimer's & Dementia. 13: P879-P880. DOI: 10.1016/J.Jalz.2017.07.265 |
0.412 |
|
| 2016 |
Tang M, Ryman DC, McDade E, Jasielec MS, Buckles VD, Cairns NJ, Fagan AM, Goate A, Marcus DS, Xiong C, Allegri RF, Chhatwal JP, Danek A, Farlow MR, Fox NC, et al. Neurological manifestations of autosomal dominant familial Alzheimer's disease: a comparison of the published literature with the Dominantly Inherited Alzheimer Network observational study (DIAN-OBS). The Lancet. Neurology. PMID 27777020 DOI: 10.1016/S1474-4422(16)30229-0 |
0.388 |
|
| 2016 |
Tosto G, Bird TD, Bennett DA, Boeve BF, Brickman AM, Cruchaga C, Faber K, Foroud TM, Farlow M, Goate AM, Graff-Radford NR, Lantigua R, Manly J, Ottman R, Rosenberg R, et al. The Role of Cardiovascular Risk Factors and Stroke in Familial Alzheimer Disease. Jama Neurology. PMID 27533593 DOI: 10.1001/Jamaneurol.2016.2539 |
0.328 |
|
| 2016 |
Lim YY, Hassenstab J, Cruchaga C, Goate A, Fagan AM, Benzinger TL, Maruff P, Snyder PJ, Masters CL, Allegri R, Chhatwal J, Farlow MR, Graff-Radford NR, Laske C, Levin J, et al. BDNF Val66Met moderates memory impairment, hippocampal function and tau in preclinical autosomal dominant Alzheimer's disease. Brain : a Journal of Neurology. PMID 27521573 DOI: 10.1093/Brain/Aww200 |
0.426 |
|
| 2016 |
Zhou Y, Bateman R, Hassenstab J, Snitz BE, Masters CL, Danek A, Laske C, Farlow MR, Ringman JM. Personality Characteristics And Alterations In Familial Alzheimer’S Disease In The Dominantly Inherited Alzheimer Network (Dian) Alzheimers & Dementia. 12. DOI: 10.1016/J.Jalz.2016.06.711 |
0.35 |
|
| 2016 |
McDade E, Weng H, Wang G, Xiong C, Fagan AM, Hassenstab J, Marcus DS, Morris JC, Benzinger TL, Cairns NJ, Goate AM, Buckles V, Holtzman DM, Berman S, Ghetti B, ... Farlow MR, et al. O5-02-01: Longitudinal Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease: The Dominantly Inherited Alzheimer Network Alzheimer's & Dementia. 12: P378-P379. DOI: 10.1016/J.Jalz.2016.06.710 |
0.387 |
|
| 2016 |
Lim YY, Hassenstab J, Cruchaga C, Goate AM, Fagan AM, Lee Smith Benzinger T, Maruff P, Snyder PJ, Masters CL, Ricardo A, Chhatwal JP, Farlow MR, Graff-Radford NR, Laske C, Levin J, et al. F5-02-03: BDNF VAL66MET Moderates Cognitive Impairment, Neuronal Dysfunction and TAU in Preclinical Autosomal Dominant Alzheimer's Disease Alzheimer's & Dementia. 12: P369-P369. DOI: 10.1016/J.Jalz.2016.06.689 |
0.395 |
|
| 2016 |
Farlow MR, Gold M, Henderson S, Greer S, Vogel J, Shenkin A. A Phase 3, 26-Week, Double-Blind, Randomized, Placebo-Controlled Study Of Ac-1204 In Mild-To-Moderate Alzheimer'S Disease: Study Design And Progress Alzheimers & Dementia. 12: 1014. DOI: 10.1016/J.Jalz.2016.06.2091 |
0.375 |
|
| 2015 |
Ringman JM, Liang LJ, Zhou Y, Vangala S, Teng E, Kremen S, Wharton D, Goate A, Marcus DS, Farlow M, Ghetti B, McDade E, Masters CL, Mayeux RP, Rossor M, et al. Erratum: Early behavioural changes in familial Alzheimers disease in the Dominantly Inherited Alzheimer Network (Brain (2015) 138 (103645) (10.1093/brain/awv004)) Brain. 138. PMID 26598496 DOI: 10.1093/Brain/Awv210 |
0.353 |
|
| 2015 |
Henderson VW, Ala T, Sainani KL, Bernstein AL, Stephenson BS, Rosen AC, Farlow MR. Raloxifene for women with Alzheimer disease: A randomized controlled pilot trial. Neurology. PMID 26537053 DOI: 10.1212/Wnl.0000000000002171 |
0.397 |
|
| 2015 |
Farlow MR, Borson S, Connor SR, Grossberg GT, Mittelman MS. Quality Improvement in Skilled Nursing Facilities for Residents With Alzheimer's Disease. American Journal of Alzheimer's Disease and Other Dementias. PMID 26385946 DOI: 10.1177/1533317515603501 |
0.351 |
|
| 2015 |
Ramanan VK, Risacher SL, Nho K, Kim S, Shen L, McDonald BC, Yoder KK, Hutchins GD, West JD, Tallman EF, Gao S, Foroud TM, Farlow MR, De Jager PL, Bennett DA, et al. GWAS of longitudinal amyloid accumulation on 18F-florbetapir PET in Alzheimer's disease implicates microglial activation gene IL1RAP. Brain : a Journal of Neurology. PMID 26268530 DOI: 10.1093/Brain/Awv231 |
0.316 |
|
| 2015 |
Farlow MR, Andreasen N, Riviere ME, Vostiar I, Vitaliti A, Sovago J, Caputo A, Winblad B, Graf A. Long-term treatment with active Aβ immunotherapy with CAD106 in mild Alzheimer's disease. Alzheimer's Research & Therapy. 7: 23. PMID 25918556 DOI: 10.1186/S13195-015-0108-3 |
0.313 |
|
| 2015 |
Ringman JM, Liang LJ, Zhou Y, Vangala S, Teng E, Kremen S, Wharton D, Goate A, Marcus DS, Farlow M, Ghetti B, McDade E, Masters CL, Mayeux RP, Rossor M, et al. Early behavioural changes in familial Alzheimer's disease in the Dominantly Inherited Alzheimer Network. Brain : a Journal of Neurology. 138: 1036-45. PMID 25688083 DOI: 10.1093/Brain/Awv004 |
0.372 |
|
| 2015 |
Nho K, Kim S, Risacher SL, Shen L, Corneveaux JJ, Swaminathan S, Lin H, Ramanan VK, Liu Y, Foroud TM, Inlow MH, Siniard AL, Reiman RA, Aisen PS, Petersen RC, ... ... Farlow MR, et al. Protective variant for hippocampal atrophy identified by whole exome sequencing. Annals of Neurology. 77: 547-52. PMID 25559091 DOI: 10.1002/Ana.24349 |
0.364 |
|
| 2015 |
Wang LS, Naj AC, Graham RR, Crane PK, Kunkle BW, Cruchaga C, Murcia JD, Cannon-Albright L, Baldwin CT, Zetterberg H, Blennow K, Kukull WA, Faber KM, Schupf N, Norton MC, ... ... Farlow MR, et al. Rarity of the Alzheimer disease-protective APP A673T variant in the United States. Jama Neurology. 72: 209-16. PMID 25531812 DOI: 10.1001/Jamaneurol.2014.2157 |
0.303 |
|
| 2015 |
Farlow MR, Grossberg GT, Sadowsky CH, Meng X, Velting DM. A 24-Week, Open-Label Extension Study to Investigate the Long-term Safety, Tolerability, and Efficacy of 13.3 mg/24 h Rivastigmine Patch in Patients With Severe Alzheimer Disease. Alzheimer Disease and Associated Disorders. 29: 110-6. PMID 25437301 DOI: 10.1097/Wad.0000000000000073 |
0.327 |
|
| 2015 |
Ghetti B, Oblak AL, Abdulkader MM, Murrell JR, Richardson RM, Epperson F, Farlow MR, Matthews BR, Unverzagt FW. P1-086: Multiple proteinopathies underlying atypical dementia Alzheimer's & Dementia. 11: P372-P372. DOI: 10.1016/J.Jalz.2015.06.283 |
0.332 |
|
| 2014 |
Naj AC, Jun G, Reitz C, Kunkle BW, Perry W, Park YS, Beecham GW, Rajbhandary RA, Hamilton-Nelson KL, Wang LS, Kauwe JS, Huentelman MJ, Myers AJ, Bird TD, Boeve BF, ... ... Farlow MR, et al. Effects of multiple genetic loci on age at onset in late-onset Alzheimer disease: a genome-wide association study. Jama Neurology. 71: 1394-404. PMID 25199842 DOI: 10.1001/Jamaneurol.2014.1491 |
0.346 |
|
| 2014 |
Gu H, Zhong Z, Jiang W, Du E, Dodel R, Liu J, Farlow MR, Zheng W, Du Y. The role of choroid plexus in IVIG-induced beta-amyloid clearance. Neuroscience. 270: 168-76. PMID 24747018 DOI: 10.1016/J.Neuroscience.2014.04.011 |
0.371 |
|
| 2014 |
Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, Kieburtz K, Raman R, Sun X, Aisen PS, Siemers E, Liu-Seifert H, Mohs R. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. The New England Journal of Medicine. 370: 311-21. PMID 24450890 DOI: 10.1056/Nejmoa1312889 |
0.444 |
|
| 2014 |
Vardarajan BN, Faber KM, Bird TD, Bennett DA, Rosenberg R, Boeve BF, Graff-Radford NR, Goate AM, Farlow M, Sweet RA, Lantigua R, Medrano MZ, Ottman R, Schaid DJ, Foroud TM, et al. Age-specific incidence rates for dementia and Alzheimer disease in NIA-LOAD/NCRAD and EFIGA families: National Institute on Aging Genetics Initiative for Late-Onset Alzheimer Disease/National Cell Repository for Alzheimer Disease (NIA-LOAD/NCRAD) and Estudio Familiar de Influencia Genetica en Alzheimer (EFIGA). Jama Neurology. 71: 315-23. PMID 24425039 DOI: 10.1001/Jamaneurol.2013.5570 |
0.317 |
|
| 2014 |
Epstein NU, Guo R, Farlow MR, Singh JP, Fisher M. Medication for Alzheimer's disease and associated fall hazard: a retrospective cohort study from the Alzheimer's Disease Neuroimaging Initiative. Drugs & Aging. 31: 125-9. PMID 24357133 DOI: 10.1007/S40266-013-0143-3 |
0.417 |
|
| 2014 |
Millard SP, Lutz F, Li G, Galasko DR, Farlow MR, Quinn JF, Kaye JA, Leverenz JB, Tsuang D, Yu CE, Peskind ER, Bekris LM. Association of cerebrospinal fluid Aβ42 with A2M gene in cognitively normal subjects. Neurobiology of Aging. 35: 357-64. PMID 24011543 DOI: 10.1016/J.Neurobiolaging.2013.07.027 |
0.394 |
|
| 2014 |
Risacher SL, WuDunn D, Yoder K, West JD, McDonald B, Tallman EM, Wang Y, Gao S, Farlow MR, Saykin AJ. P3-102: VISUAL AND AUDITORY CHANGES ARE ASSOCIATED WITH NEUROIMAGING BIOMARKERS DURING PRODROMAL STAGES OF ALZHEIMER'S DISEASE Alzheimer's & Dementia. 10: P665-P666. DOI: 10.1016/J.Jalz.2014.05.1191 |
0.346 |
|
| 2014 |
Risacher SL, West JD, Tallman EM, McDonald BC, Wang Y, Epperson F, Murrell J, Benzinger TL, Bateman R, Morris JC, Farlow MR, Ghetti BF, Saykin AJ. IC-P-094: ALTERED FMRI ACTIVATION PATTERN DURING VISUAL SCENE ENCODING IN AFFECTED AND NON-AFFECTED CARRIERS OF PSEN1 AND APP MUTATIONS Alzheimer's & Dementia. 10: P53-P53. DOI: 10.1016/J.Jalz.2014.05.099 |
0.312 |
|
| 2014 |
Ghetti BF, Newell KL, Abrahamson EE, Cairns NJ, Murrell JR, Oblak AL, Unverzagt FW, Farlow MR, Epperson F, Richardson R, Dupree B, Morris JC, Klunk WE, Saykin AJ, Risacher SL, et al. IC-P-032: COMPARATIVE ANALYSIS OF PIB IN VIVO
WITH 6-CN-PIB AND Aβ-IMMUNOHISTOCHEMISTRY POSTMORTEM IN FAMILIAL ALZHEIMER DISEASE ASSOCIATED WITH THE PSEN1 I229F MUTATION Alzheimer's & Dementia. 10: P20-P21. DOI: 10.1016/J.Jalz.2014.05.036 |
0.36 |
|
| 2013 |
Farlow MR, Schmitt F, Aarsland D, Grossberg GT, Somogyi M, Meng X. Comparing clinical profiles in Alzheimer's disease and Parkinson's disease dementia. Dementia and Geriatric Cognitive Disorders Extra. 3: 281-90. PMID 24174923 DOI: 10.1159/000351861 |
0.47 |
|
| 2013 |
Ferris SH, Farlow M. Language impairment in Alzheimer's disease and benefits of acetylcholinesterase inhibitors. Clinical Interventions in Aging. 8: 1007-14. PMID 23946647 DOI: 10.2147/Cia.S39959 |
0.373 |
|
| 2013 |
Farlow MR, Grossberg GT, Sadowsky CH, Meng X, Somogyi M. A 24-week, randomized, controlled trial of rivastigmine patch 13.3 mg/24 h versus 4.6 mg/24 h in severe Alzheimer's dementia. Cns Neuroscience & Therapeutics. 19: 745-52. PMID 23924050 DOI: 10.1111/Cns.12158 |
0.333 |
|
| 2013 |
Farlow MR, Brosch JR. Immunotherapy for Alzheimer's disease. Neurologic Clinics. 31: 869-78. PMID 23896510 DOI: 10.1016/J.Ncl.2013.03.012 |
0.426 |
|
| 2013 |
Doody RS, Raman R, Farlow M, Iwatsubo T, Vellas B, Joffe S, Kieburtz K, He F, Sun X, Thomas RG, Aisen PS, Siemers E, Sethuraman G, Mohs R, et al. A phase 3 trial of semagacestat for treatment of Alzheimer's disease. The New England Journal of Medicine. 369: 341-50. PMID 23883379 DOI: 10.1056/Nejmoa1210951 |
0.41 |
|
| 2013 |
Sabbagh M, Cummings J, Christensen D, Doody R, Farlow M, Liu L, Mackell J, Fain R. Evaluating the cognitive effects of donepezil 23 mg/d in moderate and severe Alzheimer's disease: analysis of effects of baseline features on treatment response. Bmc Geriatrics. 13: 56. PMID 23742728 DOI: 10.1186/1471-2318-13-56 |
0.382 |
|
| 2013 |
Nho K, Corneveaux JJ, Kim S, Lin H, Risacher SL, Shen L, Swaminathan S, Ramanan VK, Liu Y, Foroud T, Inlow MH, Siniard AL, Reiman RA, Aisen PS, Petersen RC, ... ... Farlow MR, et al. Whole-exome sequencing and imaging genetics identify functional variants for rate of change in hippocampal volume in mild cognitive impairment. Molecular Psychiatry. 18: 781-7. PMID 23608917 DOI: 10.1038/Mp.2013.24 |
0.333 |
|
| 2013 |
Wang Y, Risacher SL, West JD, McDonald BC, Magee TR, Farlow MR, Gao S, O'Neill DP, Saykin AJ. Altered default mode network connectivity in older adults with cognitive complaints and amnestic mild cognitive impairment. Journal of Alzheimer's Disease : Jad. 35: 751-60. PMID 23481685 DOI: 10.3233/Jad-130080 |
0.368 |
|
| 2013 |
Cummings JL, Geldmacher D, Farlow M, Sabbagh M, Christensen D, Betz P. High-dose donepezil (23 mg/day) for the treatment of moderate and severe Alzheimer's disease: drug profile and clinical guidelines. Cns Neuroscience & Therapeutics. 19: 294-301. PMID 23462265 DOI: 10.1111/Cns.12076 |
0.389 |
|
| 2013 |
Ferris S, Cummings J, Christensen D, Doody R, Farlow M, Sabbagh M, Liu L, Mackell J, Fain R. Effects of donepezil 23 mg on Severe Impairment Battery domains in patients with moderate to severe Alzheimer's disease: evaluating the impact of baseline severity. Alzheimer's Research & Therapy. 5: 12. PMID 23433097 DOI: 10.1186/Alzrt166 |
0.349 |
|
| 2013 |
Dodel R, Rominger A, Bartenstein P, Barkhof F, Blennow K, Förster S, Winter Y, Bach JP, Popp J, Alferink J, Wiltfang J, Buerger K, Otto M, Antuono P, Jacoby M, ... ... Farlow M, et al. Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial. The Lancet. Neurology. 12: 233-43. PMID 23375965 DOI: 10.1016/S1474-4422(13)70014-0 |
0.354 |
|
| 2013 |
Spina S, Van Laar AD, Murrell JR, Hamilton RL, Kofler JK, Epperson F, Farlow MR, Lopez OL, Quinlan J, DeKosky ST, Ghetti B. Phenotypic variability in three families with valosin-containing protein mutation. European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies. 20: 251-8. PMID 22900631 DOI: 10.1111/J.1468-1331.2012.03831.X |
0.302 |
|
| 2013 |
Farlow M, Grossberg G, Sadowsky C, Meng X, Somgyi M. Long-term safety and efficacy of 13.3 mg/24 h rivastigmine patch in severe Alzheimer's disease: ACTivities of daily living and cognitION (ACTION) study Journal of the Neurological Sciences. 333. DOI: 10.1016/J.Jns.2013.07.1252 |
0.374 |
|
| 2013 |
Grossberg G, Farlow M, Meng X, Somogyi M. Efficacy and safety of high-dose 13.3 mg/24 h rivastigmine patch in severe Alzheimer's disease with and without concomitant memantine use Journal of the Neurological Sciences. 333. DOI: 10.1016/J.Jns.2013.07.1244 |
0.349 |
|
| 2013 |
Risacher S, Kim S, Klaunig J, Shen L, McDonald B, Farlow M, Ghetti B, Gao S, Wang Z, Zhou S, Saykin A. P1-051: DNA damage in peripheral blood cells is associated with Alzheimer's-related plasma proteins in individuals at risk for progression to Alzheimer's disease Alzheimer's & Dementia. 9: P171-P171. DOI: 10.1016/J.Jalz.2013.05.272 |
0.368 |
|
| 2013 |
Farlow M, Grossberg G, Sadowsky C, Meng X, Somogyi M. A 24-week, open-label extension to the ACTivities of daily living and cognitION (ACTION) study: Long-term safety, tolerability and efficacy of a 13.3 mg/24 h rivastigmine patch in people with severe Alzheimer's disease Alzheimers & Dementia. 9: 655. DOI: 10.1016/J.Jalz.2013.05.1344 |
0.344 |
|
| 2013 |
Swaminathan S, Nho K, Risacher S, Yoder K, Kim S, Shen L, Tallman E, McDonald B, Hutchins G, Fletcher J, Farlow M, Ghetti B, Foroud T, Saykin A. IC-P-137: Gene-based analyses of microglial activation on [11C] PBR28 PET in older adults at risk for Alzheimer's disease Alzheimer's & Dementia. 9: P81-P81. DOI: 10.1016/J.Jalz.2013.05.134 |
0.329 |
|
| 2013 |
Vardarajan B, Bennett D, Bird T, Boeve B, Farlow M, Foroud T, Goate A, Graff-Radford N, Ottman R, Rosenberg RN, Schaid D, Sweet R, Tsuang D, Bennett J, Davis B, et al. Age-specific incidence rates of Alzheimer's disease in family members participating in the NIA-LOAD genetics study Alzheimers & Dementia. 9. DOI: 10.1016/J.Jalz.2013.05.1266 |
0.338 |
|
| 2013 |
Wang Y, West J, Risacher S, McDonald B, Tallman E, Ghetti B, Farlow M, Gao S, O'Neill D, Saykin A. IC-P-117: Characterization of regional cerebral blood flow in mild cognitive impairment and older adults with cognitive complaints Alzheimer's & Dementia. 9: P71-P71. DOI: 10.1016/J.Jalz.2013.05.114 |
0.373 |
|
| 2013 |
Risacher S, Kim S, Klaunig J, Shen L, McDonald B, Farlow M, Ghetti B, Gao S, Wang Z, Zhou S, Saykin A. IC-P-109: DNA damage in peripheral blood cells is associated with Alzheimer's disease (AD)-related plasma proteins in individuals at risk for progression to AD Alzheimer's & Dementia. 9: P64-P64. DOI: 10.1016/J.Jalz.2013.05.106 |
0.383 |
|
| 2013 |
Schneider L, Porsteinsson A, Farlow M, Shimakura A, Nakagawa M, Iwakami N. O3-06-06: The neuroprotective and neurotrophic agent T-817MA for Alzheimer's disease: Randomized, double-blind, placebo-controlled proof-of-concept trial outcomes Alzheimer's & Dementia. 9: P530-P531. DOI: 10.1016/J.Jalz.2013.04.272 |
0.325 |
|
| 2013 |
Farlow M, Meng X, Somogyi M. Efficacy, safety and tolerability of rivastigmine patch 13.3 mg/24 h (15 cm2) versus 4.6 mg/24 h (5 cm2) in patients with severe Alzheimer's disease: results of the ACTivities of daily living and cognitION (ACTION) study American Journal of Geriatric Psychiatry. 21. DOI: 10.1016/J.Jagp.2012.12.185 |
0.353 |
|
| 2012 |
Farlow M, Arnold SE, van Dyck CH, Aisen PS, Snider BJ, Porsteinsson AP, Friedrich S, Dean RA, Gonzales C, Sethuraman G, DeMattos RB, Mohs R, Paul SM, Siemers ER. Safety and biomarker effects of solanezumab in patients with Alzheimer's disease. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 8: 261-71. PMID 22672770 DOI: 10.1016/J.Jalz.2011.09.224 |
0.389 |
|
| 2012 |
Doody RS, Geldmacher DS, Farlow MR, Sun Y, Moline M, Mackell J. Efficacy and safety of donepezil 23 mg versus donepezil 10 mg for moderate-to-severe Alzheimer's disease: a subgroup analysis in patients already taking or not taking concomitant memantine. Dementia and Geriatric Cognitive Disorders. 33: 164-73. PMID 22572767 DOI: 10.1159/000338236 |
0.345 |
|
| 2012 |
Bekris LM, Lutz F, Li G, Galasko DR, Farlow MR, Quinn JF, Kaye JA, Leverenz JB, Tsuang DW, Montine TJ, Peskind ER, Yu CE. ADAM10 expression and promoter haplotype in Alzheimer's disease. Neurobiology of Aging. 33: 2229.e1-2229.e9. PMID 22572541 DOI: 10.1016/J.Neurobiolaging.2012.03.013 |
0.396 |
|
| 2012 |
Barral S, Bird T, Goate A, Farlow MR, Diaz-Arrastia R, Bennett DA, Graff-Radford N, Boeve BF, Sweet RA, Stern Y, Wilson RS, Foroud T, Ott J, Mayeux R. Genotype patterns at PICALM, CR1, BIN1, CLU, and APOE genes are associated with episodic memory. Neurology. 78: 1464-71. PMID 22539578 DOI: 10.1212/Wnl.0B013E3182553C48 |
0.324 |
|
| 2012 |
Doody RS, Cummings JL, Farlow MR. Reviewing the role of donepezil in the treatment of Alzheimer's disease. Current Alzheimer Research. 9: 773-81. PMID 22175653 DOI: 10.2174/156720512802455412 |
0.436 |
|
| 2012 |
Farlow M, Meng X, Rensch S, Somogyi M. Efficacy, safety and tolerability of rivastigmine patch 13.3 mg/24 h (15 cm2) versus 4.6 mg/24 h (5 cm2) in patients with severe Alzheimer's disease: Results of the ACTivities of daily living and cognitION (ACTION) study Alzheimers & Dementia. 8. DOI: 10.1016/J.Jalz.2013.08.069 |
0.353 |
|
| 2012 |
Yan J, Li T, McDonald B, Risacher S, WuDunn D, Farlow M, Pepin SM, Flashman L, Wishart H, Santulli R, Saykin A, Shen L. P2-041: Visual contrast sensitivity as a novel biomarker: Discriminative analysis using elastic net to classify Alzheimer's disease, MCI and older adults with cognitive complaints Alzheimer's & Dementia. 8: P277-P278. DOI: 10.1016/J.Jalz.2012.05.744 |
0.373 |
|
| 2012 |
Graf A, Andreasen N, Farlow M, Riviere M, Quarg P, Caputo A, Vostiar I, Winblad B, Orgogozo J. Long-term administration of active immunotherapy CAD106 in phase IIa open-label extension studies in Alzheimer's disease patients Alzheimers & Dementia. 8: 182. DOI: 10.1016/J.Jalz.2012.05.493 |
0.354 |
|
| 2012 |
West J, Wang Y, Magee T, McDonald B, Risacher S, Shen L, Ramanan V, Kim S, O'Neill D, Farlow M, Ghetti B, Saykin A. IC-P-060: Hippocampal subfield atrophy on 3T MRI in prodromal Alzheimer's disease and older adults with cognitive complaints Alzheimer's & Dementia. 8: P36-P36. DOI: 10.1016/J.Jalz.2012.05.093 |
0.366 |
|
| 2011 |
Farlow MR, Doraiswamy PM, Meng X, Cooke K, Somogyi M. The effect of vascular risk factors on the efficacy of rivastigmine patch and capsule treatment in Alzheimer's disease. Dementia and Geriatric Cognitive Disorders Extra. 1: 150-62. PMID 22163241 DOI: 10.1159/000328745 |
0.417 |
|
| 2011 |
Gu H, Wei X, Chen S, Kurz A, Müller U, Gasser T, Dodel RC, Farlow MR, Du Y. Association of clusterin gene polymorphisms with late-onset Alzheimer's disease. Dementia and Geriatric Cognitive Disorders. 32: 198-201. PMID 22122982 DOI: 10.1159/000331276 |
0.311 |
|
| 2011 |
Farlow MR, Grossberg GT, Meng X, Olin J, Somogyi M. Rivastigmine transdermal patch and capsule in Alzheimer's disease: influence of disease stage on response to therapy. International Journal of Geriatric Psychiatry. 26: 1236-43. PMID 22068922 DOI: 10.1002/Gps.2669 |
0.45 |
|
| 2011 |
Farlow MR, Veloso F, Moline M, Yardley J, Brand-Schieber E, Bibbiani F, Zou H, Hsu T, Satlin A. Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer's disease. Bmc Neurology. 11: 57-57. PMID 21612646 DOI: 10.1186/1471-2377-11-57 |
0.384 |
|
| 2011 |
Wijsman EM, Pankratz ND, Choi Y, Rothstein JH, Faber KM, Cheng R, Lee JH, Bird TD, Bennett DA, Diaz-Arrastia R, Goate AM, Farlow M, Ghetti B, Sweet RA, Foroud TM, et al. Genome-wide association of familial late-onset Alzheimer's disease replicates BIN1 and CLU and nominates CUGBP2 in interaction with APOE. Plos Genetics. 7: e1001308. PMID 21379329 DOI: 10.1371/Journal.Pgen.1001308 |
0.356 |
|
| 2011 |
Boustani MA, Sachs GA, Alder CA, Munger S, Schubert CC, Guerriero Austrom M, Hake AM, Unverzagt FW, Farlow M, Matthews BR, Perkins AJ, Beck RA, Callahan CM. Implementing innovative models of dementia care: The Healthy Aging Brain Center. Aging & Mental Health. 15: 13-22. PMID 21271387 DOI: 10.1080/13607863.2010.496445 |
0.306 |
|
| 2011 |
Bekris LM, Galloway NM, Millard S, Lockhart D, Li G, Galasko DR, Farlow MR, Clark CM, Quinn JF, Kaye JA, Schellenberg GD, Leverenz JB, Seubert P, Tsuang DW, Peskind ER, et al. Amyloid precursor protein (APP) processing genes and cerebrospinal fluid APP cleavage product levels in Alzheimer's disease. Neurobiology of Aging. 32: 556.e13-23. PMID 21196064 DOI: 10.1016/J.Neurobiolaging.2010.10.020 |
0.401 |
|
| 2011 |
Gu H, Wei X, Monnot AD, Fontanilla CV, Behl M, Farlow MR, Zheng W, Du Y. Lead exposure increases levels of β-amyloid in the brain and CSF and inhibits LRP1 expression in APP transgenic mice. Neuroscience Letters. 490: 16-20. PMID 21167913 DOI: 10.1016/J.Neulet.2010.12.017 |
0.367 |
|
| 2011 |
Womack KB, Diaz-Arrastia R, Aizenstein HJ, Arnold SE, Barbas NR, Boeve BF, Clark CM, DeCarli CS, Jagust WJ, Leverenz JB, Peskind ER, Turner RS, Zamrini EY, Heidebrink JL, Burke JR, ... ... Farlow MR, et al. Temporoparietal hypometabolism in frontotemporal lobar degeneration and associated imaging diagnostic errors. Archives of Neurology. 68: 329-37. PMID 21059987 DOI: 10.1001/Archneurol.2010.295 |
0.328 |
|
| 2011 |
Rominger A, Foerster S, Zach C, Dodel R, Blennow K, Barkhof F, Wietek S, Haag S, Farlow M, Jessen F, Bartenstein P. Brain glucose metabolism in patients with mild to moderate Alzheimer's disease before and after six months treatment with intravenous immunoglobulin (octagam 10%): A phase II double blind, placebo-controlled multi-center study Alzheimers & Dementia. 7. DOI: 10.1016/J.Jalz.2011.09.176 |
0.344 |
|
| 2011 |
Winblad B, Farlow M, Blennow K, Vostiar I, Imbert G, Tomovic A, Quarg P, Riviere M, Andreasen N, Graf A. Aβ-specific antibodies induced by active immunotherapy CAD106 engage Aβ in plasma in AD patients Alzheimers & Dementia. 7. DOI: 10.1016/J.Jalz.2011.05.973 |
0.357 |
|
| 2011 |
Farlow M, Richardson S, Mackell J, Sun Y. Long-term safety and tolerability of donepezil 23 mg in patients with moderate-to-severe Alzheimer's disease: An 18-month analysis Alzheimers & Dementia. 7. DOI: 10.1016/J.Jalz.2011.05.2242 |
0.366 |
|
| 2011 |
Wang Y, West J, Magee T, McDonald B, Risacher S, Farlow M, O'Neill D, Saykin A. IC-P-078: Resting-state fMRI activity profile in prodromal Alzheimer's disease and older adults with cognitive complaints Alzheimer's & Dementia. 7: S40-S41. DOI: 10.1016/J.Jalz.2011.05.144 |
0.362 |
|
| 2010 |
Schmitt FA, Farlow MR, Meng X, Tekin S, Olin JT. Efficacy of rivastigmine on executive function in patients with Parkinson's disease dementia. Cns Neuroscience & Therapeutics. 16: 330-6. PMID 20950329 DOI: 10.1111/J.1755-5949.2010.00182.X |
0.419 |
|
| 2010 |
Farlow MR, Grossberg G, Gauthier S, Meng X, Olin JT. The ACTION study: methodology of a trial to evaluate safety and efficacy of a higher dose rivastigmine transdermal patch in severe Alzheimer's disease. Current Medical Research and Opinion. 26: 2441-7. PMID 20828359 DOI: 10.1185/03007995.2010.513849 |
0.377 |
|
| 2010 |
Farlow MR, Salloway S, Tariot PN, Yardley J, Moline ML, Wang Q, Brand-Schieber E, Zou H, Hsu T, Satlin A. Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double-blind study. Clinical Therapeutics. 32: 1234-51. PMID 20678673 DOI: 10.1016/J.Clinthera.2010.06.019 |
0.331 |
|
| 2010 |
Epstein NU, Saykin AJ, Risacher SL, Gao S, Farlow MR. Differences in medication use in the Alzheimer's disease neuroimaging initiative: analysis of baseline characteristics. Drugs & Aging. 27: 677-86. PMID 20658795 DOI: 10.2165/11538260-000000000-00000 |
0.459 |
|
| 2010 |
Farlow MR. Should the ApoE genotype be a covariate for clinical trials in Alzheimer disease? Alzheimer's Research & Therapy. 2: 15. PMID 20537201 DOI: 10.1186/Alzrt39 |
0.442 |
|
| 2010 |
Cummings JL, Ferris SH, Farlow MR, Olin JT, Meng X. Effects of rivastigmine transdermal patch and capsule on aspects of clinical global impression of change in Alzheimer's disease: a retrospective analysis. Dementia and Geriatric Cognitive Disorders. 29: 406-12. PMID 20502014 DOI: 10.1159/000296073 |
0.406 |
|
| 2010 |
Farlow MR, Cummings JL, Olin JT, Meng X. Effects of oral rivastigmine on cognitive domains in mild-to-moderate Alzheimer's disease. American Journal of Alzheimer's Disease and Other Dementias. 25: 347-52. PMID 20392862 DOI: 10.1177/1533317510365344 |
0.386 |
|
| 2010 |
Siemers ER, Friedrich S, Dean RA, Gonzales CR, Farlow MR, Paul SM, Demattos RB. Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease. Clinical Neuropharmacology. 33: 67-73. PMID 20375655 DOI: 10.1097/Wnf.0B013E3181Cb577A |
0.399 |
|
| 2010 |
Sadowsky CH, Farlow MR, Meng X, Olin JT. Safety and tolerability of rivastigmine transdermal patch compared with rivastigmine capsules in patients switched from donepezil: data from three clinical trials. International Journal of Clinical Practice. 64: 188-93. PMID 20089009 DOI: 10.1111/J.1742-1241.2009.02253.X |
0.347 |
|
| 2010 |
Cummings JL, Farlow MR, Meng X, Tekin S, Olin JT. Rivastigmine transdermal patch skin tolerability: results of a 1-year clinical trial in patients with mild-to-moderate Alzheimer's disease. Clinical Drug Investigation. 30: 41-9. PMID 19995097 DOI: 10.2165/11531270-000000000-00000 |
0.387 |
|
| 2010 |
Farlow MR, Alva G, Meng X, Olin JT. A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimer's disease: a post hoc analysis. Current Medical Research and Opinion. 26: 263-9. PMID 19929593 DOI: 10.1185/03007990903434914 |
0.438 |
|
| 2010 |
Austrom MG, Bachman J, Altmeyer L, Gao S, Farlow M. A collaborative Alzheimer disease research exchange using a community-based Helpline as a recruitment tool. Alzheimer Disease & Associated Disorders. 24: 1. DOI: 10.1097/Wad.0B013E3181F11F8D |
0.338 |
|
| 2010 |
Farlow MR, Jessen F, Wietek S, Melsen T, Haag S, Dodel R. Randomized double-blind placebo-controlled dose-finding trial of intravenous immunoglobulin (octagam® 10%, octapharma AG) in patients with Alzheimer's disease Alzheimers & Dementia. 6. DOI: 10.1016/J.Jalz.2010.05.1783 |
0.365 |
|
| 2010 |
Unverzagt FW, Farlow MR, Gao S, Saykin AJ, Murrell JR, Risacher SL, Lane KA, West JD, Matthews BR, Piccardo P, Miravalle L, Vidal RG, Ghetti B. P3-156: Cognition and brain structure in Gerstmann-Straussler-Scheinker disease (PRNP F198S) Alzheimer's & Dementia. 6: S495-S495. DOI: 10.1016/J.Jalz.2010.05.1654 |
0.326 |
|
| 2010 |
Saykin AJ, Yoder KK, Risacher SL, MaGee TR, McDonald BC, Zheng Q, Wang M, Mock BH, Shen L, West JD, Fletcher JW, Farlow MR, Hutchins GD. IC-01-04: Neuroinflammation and amyloid deposition: Concurrent [11
C]PBR28 and [11
C]PIB PET imaging in patients with Alzheimer's disease, mild cognitive impairment, and older adults with cognitive complaints Alzheimer's & Dementia. 6: S3-S4. DOI: 10.1016/J.Jalz.2010.05.010 |
0.376 |
|
| 2009 |
Farlow MR. Treatment of mild cognitive impairment (MCI). Current Alzheimer Research. 6: 362-7. PMID 19689235 DOI: 10.2174/156720509788929282 |
0.445 |
|
| 2009 |
Ferris S, Lane R, Sfikas N, Winblad B, Farlow M, Feldman HH. Effects of gender on response to treatment with rivastigmine in mild cognitive impairment: A post hoc statistical modeling approach. Gender Medicine. 6: 345-55. PMID 19682661 DOI: 10.1016/J.Genm.2009.06.004 |
0.413 |
|
| 2009 |
Farlow MR. The SERAD study of the safety and efficacy of galantamine in severe Alzheimer's disease. The Lancet. Neurology. 8: 22-3. PMID 19042160 DOI: 10.1016/S1474-4422(08)70262-X |
0.381 |
|
| 2008 |
Campbell N, Ayub A, Boustani MA, Fox C, Farlow M, Maidment I, Howard R. Impact of cholinesterase inhibitors on behavioral and psychological symptoms of Alzheimer's disease: a meta-analysis. Clinical Interventions in Aging. 3: 719-728. PMID 19281064 DOI: 10.2147/Cia.S4250 |
0.37 |
|
| 2008 |
Farlow MR. Randomized clinical trial results for donepezil in Alzheimer's disease: is the treatment glass half full or half empty? Journal of the American Geriatrics Society. 56: 1566-7. PMID 18808602 DOI: 10.1111/J.1532-5415.2008.01853.X |
0.379 |
|
| 2008 |
Farlow MR, Graham SM, Alva G. Memantine for the treatment of Alzheimer's disease: tolerability and safety data from clinical trials. Drug Safety. 31: 577-85. PMID 18558791 DOI: 10.2165/00002018-200831070-00003 |
0.356 |
|
| 2008 |
Bekris LM, Millard SP, Galloway NM, Vuletic S, Albers JJ, Li G, Galasko DR, DeCarli C, Farlow MR, Clark CM, Quinn JF, Kaye JA, Schellenberg GD, Tsuang D, Peskind ER, et al. Multiple SNPs within and surrounding the apolipoprotein E gene influence cerebrospinal fluid apolipoprotein E protein levels. Journal of Alzheimer's Disease : Jad. 13: 255-66. PMID 18430993 DOI: 10.3233/Jad-2008-13303 |
0.34 |
|
| 2008 |
Farlow MR, Miller ML, Pejovic V. Treatment options in Alzheimer's disease: maximizing benefit, managing expectations. Dementia and Geriatric Cognitive Disorders. 25: 408-22. PMID 18391487 DOI: 10.1159/000122962 |
0.384 |
|
| 2008 |
Lane R, Feldman HH, Meyer J, He Y, Ferris SH, Nordberg A, Darreh-Shori T, Soininen H, Pirttilä T, Farlow MR, Sfikas N, Ballard C, Greig NH. Synergistic effect of apolipoprotein E epsilon4 and butyrylcholinesterase K-variant on progression from mild cognitive impairment to Alzheimer's disease. Pharmacogenetics and Genomics. 18: 289-98. PMID 18334913 DOI: 10.1097/Fpc.0B013E3282F63F29 |
0.402 |
|
| 2008 |
Farlow MR, Cummings J. A modern hypothesis: The distinct pathologies of dementia associated with Parkinson's disease versus Alzheimer's disease. Dementia and Geriatric Cognitive Disorders. 25: 301-8. PMID 18311077 DOI: 10.1159/000119104 |
0.445 |
|
| 2008 |
Spina S, Farlow MR, Unverzagt FW, Kareken DA, Murrell JR, Fraser G, Epperson F, Crowther RA, Spillantini MG, Goedert M, Ghetti B. The tauopathy associated with mutation +3 in intron 10 of Tau: characterization of the MSTD family. Brain : a Journal of Neurology. 131: 72-89. PMID 18065436 DOI: 10.1093/Brain/Awm280 |
0.383 |
|
| 2008 |
Spina S, Laar ADV, Murrell JR, Courten-Myers Gd, Hamilton RL, Vidal R, Farlow MR, Quinlan J, DeKosky ST, Ghetti B. O2-05-03: Inclusion body myopathy with paget disease of the bone and frontotemporal dementia: New families, a novel mutation, and a new clinical presentation Alzheimers & Dementia. 4. DOI: 10.1016/J.Jalz.2008.05.342 |
0.308 |
|
| 2008 |
Ghetti B, Hake AM, Murrell JR, Epperson F, Farlow MR, Vidal R, Spina S. P3-221: Familial Alzheimer's disease associated with the V717L amyloid precursor protein gene mutation: Neuropathological characterization Alzheimers & Dementia. 4. DOI: 10.1016/J.Jalz.2008.05.1788 |
0.402 |
|
| 2008 |
Raskind MA, Petrie EC, Wilkinson CW, Li G, Chi P, Galasko DR, Quinn JF, Kaye JA, Clark CM, Farlow MR, DeCarli C, Wang LY, Leverenz JB, Schellenberg GD, Peskind ER. P3-090: Cerebrospinal fluid norepinephrine increases with aging, Alzheimers disease and APOE4 genotype Alzheimers & Dementia. 4. DOI: 10.1016/J.Jalz.2008.05.1654 |
0.37 |
|
| 2008 |
Li G, Galasko DR, Quinn JF, Kaye JA, Clark CM, Farlow MR, DeCarli C, Raskind MA, Petrie EC, Leverenz J, Shofer JB, Schellenberg GD, Cottrell B, Peskind ER. P3-085: Age- and APOE-related cerebrospinal fluid Alzheimer's disease biomarker changes in normal controls Alzheimer's & Dementia. 4: T542-T543. DOI: 10.1016/J.Jalz.2008.05.1649 |
0.371 |
|
| 2007 |
Siemers ER, Dean RA, Friedrich S, Ferguson-Sells L, Gonzales C, Farlow MR, May PC. Safety, tolerability, and effects on plasma and cerebrospinal fluid amyloid-beta after inhibition of gamma-secretase. Clinical Neuropharmacology. 30: 317-25. PMID 18090456 DOI: 10.1097/Wnf.0B013E31805B7660 |
0.318 |
|
| 2007 |
Farlow MR. Rivastigmine three times daily improves cognition and response in Alzheimer's disease. Evidence-Based Mental Health. 10: 116. PMID 17962669 DOI: 10.1136/Ebmh.10.4.116 |
0.411 |
|
| 2007 |
Winblad B, Grossberg G, Frölich L, Farlow M, Zechner S, Nagel J, Lane R. IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease. Neurology. 69: S14-22. PMID 17646619 DOI: 10.1212/01.Wnl.0000281847.17519.E0 |
0.407 |
|
| 2007 |
Gelfanova V, Higgs RE, Dean RA, Holtzman DM, Farlow MR, Siemers ER, Boodhoo A, Qian YW, He X, Jin Z, Fisher DL, Cox KL, Hale JE. Quantitative analysis of amyloid-beta peptides in cerebrospinal fluid using immunoprecipitation and MALDI-Tof mass spectrometry. Briefings in Functional Genomics & Proteomics. 6: 149-58. PMID 17584762 DOI: 10.1093/Bfgp/Elm010 |
0.317 |
|
| 2007 |
Feldman HH, Ferris S, Winblad B, Sfikas N, Mancione L, He Y, Tekin S, Burns A, Cummings J, del Ser T, Inzitari D, Orgogozo JM, Sauer H, Scheltens P, Scarpini E, ... ... Farlow M, et al. Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study. The Lancet. Neurology. 6: 501-12. PMID 17509485 DOI: 10.1016/S1474-4422(07)70109-6 |
0.421 |
|
| 2007 |
Farlow MR, Cummings JL. Effective pharmacologic management of Alzheimer's disease. The American Journal of Medicine. 120: 388-97. PMID 17466645 DOI: 10.1016/J.Amjmed.2006.08.036 |
0.428 |
|
| 2007 |
Edwards K, Royall DR, Hershey L, Lichter D, Hake A, Farlow M, Pasquier F, Johnson S. Efficacy and safety of galantamine in patients with dementia with Lewy bodies: a 24-week open-label study. Dementia and Geriatric Cognitive Disorders. 23: 401-405. PMID 17409748 DOI: 10.1159/000101512 |
0.366 |
|
| 2006 |
Gauthier S, Vellas B, Farlow M, Burn D. Aggressive course of disease in dementia. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 2: 210-7. PMID 19595889 DOI: 10.1016/J.Jalz.2006.03.002 |
0.419 |
|
| 2006 |
Sabbagh MN, Farlow MR, Relkin N, Beach TG. Do cholinergic therapies have disease-modifying effects in Alzheimer's disease? Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 2: 118-25. PMID 19595868 DOI: 10.1016/J.Jalz.2006.02.001 |
0.439 |
|
| 2006 |
Oe T, Ackermann BL, Inoue K, Berna MJ, Garner CO, Gelfanova V, Dean RA, Siemers ER, Holtzman DM, Farlow MR, Blair IA. Quantitative analysis of amyloid beta peptides in cerebrospinal fluid of Alzheimer's disease patients by immunoaffinity purification and stable isotope dilution liquid chromatography/negative electrospray ionization tandem mass spectrometry. Rapid Communications in Mass Spectrometry : Rcm. 20: 3723-35. PMID 17117458 DOI: 10.1002/Rcm.2787 |
0.32 |
|
| 2006 |
Farlow MR. Use of antidementia agents in vascular dementia: beyond Alzheimer disease. Mayo Clinic Proceedings. 81: 1350-8. PMID 17036561 DOI: 10.4065/81.10.1350 |
0.441 |
|
| 2006 |
Spillantini MG, Murrell JR, Goedert M, Farlow M, Klug A, Ghetti B. Mutations in the tau gene (MAPT) in FTDP-17: the family with Multiple System Tauopathy with Presenile Dementia (MSTD). Journal of Alzheimer's Disease : Jad. 9: 373-80. PMID 16914875 DOI: 10.3233/Jad-2006-9S342 |
0.37 |
|
| 2006 |
Risacher SL, Tallman EF, West JD, McDonald BC, Unverzagt FW, Apostolova LG, Farlow MR, Saykin AJ. IC-P-109: THE COGNITIVE CHANGE INDEX IS ASSOCIATED WITH TAU DEPOSITION ON [18
F]FLORTAUCIPIR Alzheimer's & Dementia. 14: P93-P94. DOI: 10.1016/J.Jalz.2018.06.2175 |
0.305 |
|
| 2006 |
Risacher SL, Tallman EF, WuDunn D, West JD, Apostolova LG, Farlow MR, Unverzagt FW, Saykin AJ. IC-P-108: COMBINATORIAL SENSORY MODALITY ASSESSMENT IN PRODROMAL ALZHEIMER'S DISEASE: RELATION TO MRI AND AMYLOID AND TAU PET Alzheimer's & Dementia. 14: P92-P93. DOI: 10.1016/J.Jalz.2018.06.2174 |
0.384 |
|
| 2006 |
Wen Q, Mustafi SM, Harezlak J, Li J, Risacher SL, West JD, Tallman EF, Farlow MR, Unverzagt FW, Apostolova LG, Saykin AJ, Wu Y. P3-396: WHITE-MATTER MICROSTRUCTURE IN EARLY STAGE ALZHEIMER'S DISEASE Alzheimer's & Dementia. 14: P1250-P1252. DOI: 10.1016/J.Jalz.2018.06.1758 |
0.361 |
|
| 2006 |
Peskind ER, Li G, Shofer J, Quinn J, Kaye J, Clark CM, Farlow M, DeCarli C, Raskind MA, Schellenberg GD, Lee VM, Galasko D. P2-134: Age and apolipoprotein E*4 effects on cerebrospinal fluid Aβ42 in cognitively normal adults Alzheimer's & Dementia. 2: S273-S273. DOI: 10.1016/J.Jalz.2006.05.972 |
0.32 |
|
| 2006 |
Cuenco KT, Zhang J, Go RCP, Friedland RP, Duara R, Kurz A, Sadovnick AD, Akomolafe A, Chui H, Petrovitch H, Tsolaki M, Obisesan TO, Sabbagh MN, Farlow M, Relkin NR, et al. P1-283: Ethnic differences in MRI scans among Alzheimer’s disease patients and unaffected siblings in the MIRAGE Study Alzheimers & Dementia. 2. DOI: 10.1016/J.Jalz.2006.05.660 |
0.329 |
|
| 2006 |
Lunetta KL, Erlich PM, Go RC, Friedland RP, Duara R, Kurz A, Dessa Sadovnick A, Akomolafe A, Chui H, Petrovitch H, Tsolaki M, Obisesan TO, Sabbagh MN, Farlow M, Relkin NR, et al. P3-165: MRI traits are heritable among Alzheimer disease cases and their siblings in the MIRAGE Study Alzheimer's & Dementia. 2: S422-S423. DOI: 10.1016/J.Jalz.2006.05.1433 |
0.376 |
|
| 2006 |
Hake AM, Farlow MR. P3-073: American Sign Language aphasia in Alzheimer disease Alzheimers & Dementia. 2. DOI: 10.1016/J.Jalz.2006.05.1340 |
0.34 |
|
| 2005 |
Schneider LS, DeKosky ST, Farlow MR, Tariot PN, Hoerr R, Kieser M. A randomized, double-blind, placebo-controlled trial of two doses of Ginkgo biloba extract in dementia of the Alzheimer's type. Current Alzheimer Research. 2: 541-51. PMID 16375657 DOI: 10.2174/156720505774932287 |
0.376 |
|
| 2005 |
Sabbagh MN, Hake AM, Ahmed S, Farlow MR. The use of memantine in dementia with Lewy bodies. Journal of Alzheimer's Disease : Jad. 7: 285-9. PMID 16131729 DOI: 10.3233/Jad-2005-7403 |
0.406 |
|
| 2005 |
Farlow MR, Small GW, Quarg P, Krause A. Efficacy of rivastigmine in Alzheimer's disease patients with rapid disease progression: results of a meta-analysis. Dementia and Geriatric Cognitive Disorders. 20: 192-7. PMID 16088144 DOI: 10.1159/000087301 |
0.417 |
|
| 2005 |
Sadowsky CH, Farlow MR, Atkinson L, Steadman J, Koumaras B, Chen M, Mirski D. Switching From Donepezil to Rivastigmine Is Well Tolerated: Results of an Open-Label Safety and Tolerability Study. Primary Care Companion to the Journal of Clinical Psychiatry. 7: 43-48. PMID 15841194 DOI: 10.4088/Pcc.V07N0201 |
0.319 |
|
| 2005 |
Lane RM, Farlow MR. Lipid homeostasis and apolipoprotein E in the development and progression of Alzheimer's disease. Journal of Lipid Research. 46: 949-68. PMID 15716586 DOI: 10.1194/Jlr.M400486-Jlr200 |
0.362 |
|
| 2005 |
Farlow MR. The search for disease modification in moderate to severe Alzheimer disease: A critical review of current evidence Neurology. 65: S25-S30. DOI: 10.1212/Wnl.65.6_Suppl_3.S25 |
0.434 |
|
| 2005 |
Farlow MR. Moderate to severe Alzheimer disease: Definition and clinical relevance Neurology. 65: S1-S4. DOI: 10.1212/Wnl.65.6_Suppl_3.S1 |
0.462 |
|
| 2004 |
Farlow MR, He Y, Tekin S, Xu J, Lane R, Charles HC. Impact of APOE in mild cognitive impairment. Neurology. 63: 1898-901. PMID 15557508 DOI: 10.1212/01.Wnl.0000144279.21502.B7 |
0.375 |
|
| 2004 |
Kurz A, Farlow M, Quarg P, Spiegel R. Disease stage in Alzheimer disease and treatment effects of rivastigmine. Alzheimer Disease & Associated Disorders. 18: 123-128. PMID 15494617 DOI: 10.1097/01.Wad.0000127445.00442.A1 |
0.445 |
|
| 2004 |
Dodel RC, Du Y, Depboylu C, Hampel H, Frölich L, Haag A, Hemmeter U, Paulsen S, Teipel SJ, Brettschneider S, Spottke A, Nölker C, Möller HJ, Wei X, Farlow M, et al. Intravenous immunoglobulins containing antibodies against β-amyloid for the treatment of Alzheimer's disease Journal of Neurology, Neurosurgery and Psychiatry. 75: 1472-1474. PMID 15377700 DOI: 10.1136/Jnnp.2003.033399 |
0.422 |
|
| 2004 |
Farlow M, Lane R, Kudaravalli S, He Y. Differential qualitative responses to rivastigmine in APOE epsilon 4 carriers and noncarriers. The Pharmacogenomics Journal. 4: 332-5. PMID 15289797 DOI: 10.1038/Sj.Tpj.6500267 |
0.394 |
|
| 2004 |
Hake AM, Farlow MR. On the horizon: pathways for drug development in Alzheimer's disease. Clinics in Geriatric Medicine. 20: 141-52. PMID 15062492 DOI: 10.1016/S0749-0690(03)00073-9 |
0.427 |
|
| 2004 |
Hampel H, Teipel SJ, Fuchsberger T, Andreasen N, Wiltfang J, Otto M, Shen Y, Dodel R, Du Y, Farlow M, Möller HJ, Blennow K, Buerger K. Value of CSF β-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment Molecular Psychiatry. 9: 705-710. PMID 14699432 DOI: 10.1038/Sj.Mp.4001473 |
0.431 |
|
| 2004 |
Edwards KR, Hershey L, Wray L, Bednarczyk EM, Lichter D, Farlow M, Johnson S. Efficacy and safety of galantamine in patients with dementia with Lewy bodies: a 12-week interim analysis. Dementia and Geriatric Cognitive Disorders. 17: 40-48. PMID 14676468 DOI: 10.1159/000074681 |
0.332 |
|
| 2004 |
Roher AE, Kokjohn TA, Esh C, Weiss N, Childress J, Kalback W, Luehrs DC, Lopez J, Brune D, Kuo YM, Farlow M, Murrell J, Vidal R, Ghetti B. The human amyloid-beta precursor protein770 mutation V717F generates peptides longer than amyloid-beta-(40-42) and flocculent amyloid aggregates. The Journal of Biological Chemistry. 279: 5829-36. PMID 14645225 DOI: 10.1074/Jbc.M311380200 |
0.349 |
|
| 2004 |
Wei X, Zhao L, Gao F, Dodel R, Hampel H, Farlow M, Du Y. P4-107 A genetic variation of the interleukin-1 receptor agonist reduces the risk for late onset sporadic Alzheimer's disease Neurobiology of Aging. 25: S505. DOI: 10.1016/S0197-4580(04)81665-8 |
0.349 |
|
| 2004 |
Faltraco F, Teipel SJ, Dodel R, Du Y, Farlow MR, Shen Y, Moeller H, Hampel H. P4-073 CDC2 gene polymorphism is associated with cognitive decline in Alzheimer's disease Neurobiology of Aging. 25. DOI: 10.1016/S0197-4580(04)81631-2 |
0.41 |
|
| 2004 |
Hake AM, Schneider LS, Tariot PN, Farlow MR. P1-063 The rate of decline in mild to moderate stage Alzheimer disease is associated with increased symptoms of depression Neurobiology of Aging. 25: S113. DOI: 10.1016/S0197-4580(04)80377-4 |
0.335 |
|
| 2003 |
Gauthier S, Emre M, Farlow MR, Bullock R, Grossberg GT, Potkin SG. Strategies for continued successful treatment of Alzheimer's disease: switching cholinesterase inhibitors. Current Medical Research and Opinion. 19: 707-14. PMID 14687441 DOI: 10.1185/030079903125002450 |
0.351 |
|
| 2003 |
Clark CM, Xie S, Chittams J, Ewbank D, Peskind E, Galasko D, Morris JC, McKeel DW, Farlow M, Weitlauf SL, Quinn J, Kaye J, Knopman D, Arai H, Doody RS, et al. Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses? Archives of Neurology. 60: 1696-702. PMID 14676043 DOI: 10.1001/Archneur.60.12.1696 |
0.318 |
|
| 2003 |
Farlow MR. Clinical pharmacokinetics of galantamine. Clinical Pharmacokinetics. 42: 1383-92. PMID 14674789 DOI: 10.2165/00003088-200342150-00005 |
0.411 |
|
| 2003 |
Farlow MR. Update on rivastigmine. The Neurologist. 9: 230-4. PMID 14587496 DOI: 10.1097/01.Nrl.0000087724.73783.5F |
0.431 |
|
| 2003 |
Lahiri DK, Farlow MR. Review: cholinesterase inhibitors have a modest effect on neuropsychiatric and functional outcomes in Alzheimer's disease. Evidence-Based Mental Health. 6: 94. PMID 12893805 DOI: 10.1136/Ebmh.6.3.94 |
0.36 |
|
| 2003 |
Farlow M, Potkin S, Koumaras B, Veach J, Mirski D. Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial. Jama Neurology. 60: 843-848. PMID 12810489 DOI: 10.1001/Archneur.60.6.843 |
0.383 |
|
| 2003 |
Aisen PS, Schafer KA, Grundman M, Pfeiffer E, Sano M, Davis KL, Farlow MR, Jin S, Thomas RG, Thal LJ. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. Jama. 289: 2819-26. PMID 12783912 DOI: 10.1001/Jama.289.21.2819 |
0.326 |
|
| 2003 |
Grundman M, Capparelli E, Kim HT, Morris JC, Farlow M, Rubin EH, Heidebrink J, Hake A, Ho G, Schultz AN, Schafer K, Houston W, Thomas R, Thal LJ. A multicenter, randomized, placebo controlled, multiple-dose, safety and pharmacokinetic study of AIT-082 (Neotrofin) in mild Alzheimer's disease patients. Life Sciences. 73: 539-53. PMID 12770610 DOI: 10.1016/S0024-3205(03)00320-5 |
0.356 |
|
| 2003 |
Zubenko GS, Zubenko WN, McPherson S, Spoor E, Marin DB, Farlow MR, Smith GE, Geda YE, Cummings JL, Petersen RC, Sunderland T. A collaborative study of the emergence and clinical features of the major depressive syndrome of Alzheimer's disease. The American Journal of Psychiatry. 160: 857-66. PMID 12727688 DOI: 10.1176/Appi.Ajp.160.5.857 |
0.381 |
|
| 2003 |
Lahiri DK, Farlow MR, Sambamurti K, Greig NH, Giacobini E, Schneider LS. A critical analysis of new molecular targets and strategies for drug developments in Alzheimer's disease. Current Drug Targets. 4: 97-112. PMID 12558063 DOI: 10.2174/1389450033346957 |
0.415 |
|
| 2003 |
DeKosky ST, Ikonomovic MD, Wang X, Farlow M, Wisniewski S, Lopez OL, Becker JT, Saxton J, Klunk WE, Sweet R, Kaufer DI, Kamboh MI. Plasma and cerebrospinal fluid alpha1-antichymotrypsin levels in Alzheimer's disease: correlation with cognitive impairment. Annals of Neurology. 53: 81-90. PMID 12509851 DOI: 10.1002/Ana.10414 |
0.442 |
|
| 2003 |
Farlow M. Efficacy of donepezil in vascular dementia Neurology. 61: 429-429. DOI: 10.1212/Wnl.61.4.429 |
0.414 |
|
| 2003 |
Emre M, Farlow M, Bullock R, Gauthier S, Grossberg G, Potkin SG. Cholinesterase inhibitors in Alzheimer's disease: A consensus view on managing treatment failure Primary Care Psychiatry. 9: 29-30. DOI: 10.1185/135525703125002739 |
0.348 |
|
| 2002 |
Farlow M. A clinical overview of cholinesterase inhibitors in Alzheimer's disease. International Psychogeriatrics. 14: 93-126. PMID 12636182 DOI: 10.1017/S1041610203008688 |
0.433 |
|
| 2002 |
Lahiri DK, Kotwal GJ, Farlow MR, Sima A, Kupsky W, Sarkar FH, Sambamurti K. The role of the carboxyl-terminal fragments of amyloid precursor protein in Alzheimer's disease. Annals of the New York Academy of Sciences. 973: 334-9. PMID 12485889 DOI: 10.1111/J.1749-6632.2002.Tb04661.X |
0.382 |
|
| 2002 |
Dodel R, Hampel H, Depboylu C, Lin S, Gao F, Schock S, Jäckel S, Wei X, Buerger K, Höft C, Hemmer B, Möller HJ, Farlow M, Oertel WH, Sommer N, et al. Human antibodies against amyloid beta peptide: a potential treatment for Alzheimer's disease. Annals of Neurology. 52: 253-6. PMID 12210803 DOI: 10.1002/Ana.10253 |
0.338 |
|
| 2002 |
Lahiri DK, Utsuki T, Chen D, Farlow MR, Shoaib M, Ingram DK, Greig NH. Nicotine reduces the secretion of Alzheimer's beta-amyloid precursor protein containing beta-amyloid peptide in the rat without altering synaptic proteins. Annals of the New York Academy of Sciences. 965: 364-72. PMID 12105112 DOI: 10.1111/J.1749-6632.2002.Tb04178.X |
0.312 |
|
| 2002 |
Grundman M, Farlow M, Peavy G, Kim HT, Capparelli E, Schultz AN, Salmon DP, Ferris SH, Mobs R, Thomas RG, Schafer K, Campbell K, Hake AM, Schoos B, Thal LJ, et al. A phase I study of AIT-082 in healthy elderly volunteers. Journal of Molecular Neuroscience : Mn. 18: 283-93. PMID 12059047 DOI: 10.1385/Jmn:18:3:283 |
0.308 |
|
| 2002 |
Dodel RC, Du Y, Depboylu C, Kurz A, Eastwood B, Farlow M, Oertel WH, Müller U, Riemenschneider M. A polymorphism in the cystatin C promoter region is not associated with an increased risk of AD Neurology. 58: 664. PMID 11865157 DOI: 10.1212/Wnl.58.4.664 |
0.366 |
|
| 2002 |
Lahiri DK, Farlow MR, Greig NH, Sambamurti K. Current drug targets for Alzheimer's disease treatment Drug Development Research. 56: 267-281. DOI: 10.1002/Ddr.10081 |
0.425 |
|
| 2001 |
Hake AM, Farlow MR. New concepts in the drug therapy of Alzheimer's disease. Expert Opinion On Pharmacotherapy. 2: 1975-83. PMID 11825329 DOI: 10.1517/14656566.2.12.1975 |
0.379 |
|
| 2001 |
Takao M, Ghetti B, Murrell JR, Unverzagt FW, Giaccone G, Tagliavini F, Bugiani O, Piccardo P, Hulette CM, Crain BJ, Farlow MR, Heyman A. Ectopic white matter neurons, a developmental abnormality that may be caused by the PSEN1 S169L mutation in a case of familial AD with myoclonus and seizures. Journal of Neuropathology and Experimental Neurology. 60: 1137-52. PMID 11764087 DOI: 10.1093/Jnen/60.12.1137 |
0.346 |
|
| 2001 |
Siakotos AN, Hutchins GD, Farlow MR, Katz ML. Assessment of dietary therapies in a canine model of Batten disease. European Journal of Paediatric Neurology : Ejpn : Official Journal of the European Paediatric Neurology Society. 5: 151-6. PMID 11588988 DOI: 10.1053/Ejpn.2000.0453 |
0.331 |
|
| 2001 |
Du Y, Dodel R, Hampel H, Buerger K, Lin S, Eastwood B, Bales K, Gao F, Moeller HJ, Oertel W, Farlow M, Paul S. Reduced levels of amyloid β-peptide antibody in Alzheimer disease Neurology. 57: 801-805. PMID 11552007 DOI: 10.1212/Wnl.57.5.801 |
0.354 |
|
| 2001 |
Morris JC, Farlow MR, Ferris SH, Kurz AF, Maelicke A, Rasmusen L, Wilkinson D, Yan B. Therapeutic continuity in Alzheimer's disease: switching patients to galantamine. Panel discussion: recommendations for prescribers. Clinical Therapeutics. 23: A31-9. PMID 11396870 DOI: 10.1016/S0149-2918(01)80166-1 |
0.393 |
|
| 2001 |
Farlow MR. Pharmacokinetic profiles of current therapies for Alzheimer's disease: implications for switching to galantamine. Clinical Therapeutics. 23: A13-24. PMID 11396867 DOI: 10.1016/S0149-2918(01)80164-8 |
0.371 |
|
| 2001 |
Farlow MR, Hake A, Messina J, Hartman R, Veach J, Anand R. Response of patients with Alzheimer disease to rivastigmine treatment is predicted by the rate of disease progression. Archives of Neurology. 58: 417-22. PMID 11255445 DOI: 10.1001/Archneur.58.3.417 |
0.388 |
|
| 2001 |
Kareken DA, Doty RL, Moberg PJ, Mosnik D, Chen SH, Farlow MR, Hutchins GD. Olfactory-evoked regional cerebral blood flow in Alzheimer's disease. Neuropsychology. 15: 18-29. PMID 11216885 DOI: 10.1037//0894-4105.15.1.18 |
0.305 |
|
| 2001 |
Yazaki M, Liepnieks JJ, Murrell JR, Takao M, Guenther B, Piccardo P, Farlow MR, Ghetti B, Benson MD. Biochemical characterization of a neuroserpin variant associated with hereditary dementia. The American Journal of Pathology. 158: 227-33. PMID 11141496 DOI: 10.1016/S0002-9440(10)63961-2 |
0.311 |
|
| 2001 |
Farlow M. Reply to the Letter by Deleu: Rivastigmine in the Treatment of Alzheimer’s Disease European Neurology. 46: 111-111. DOI: 10.1159/000050780 |
0.329 |
|
| 2000 |
Lahiri DK, Farlow MR, Hintz N, Utsuki T, Greig NH. Cholinesterase inhibitors, beta-amyloid precursor protein and amyloid beta-peptides in Alzheimer's disease. Acta Neurologica Scandinavica. Supplementum. 176: 60-7. PMID 11273593 DOI: 10.1034/J.1600-0404.2000.00309.X |
0.394 |
|
| 2000 |
Farlow M, Anand R, Messina J, Hartman R, Veach J. A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease. European Neurology. 44: 236-41. PMID 11096224 DOI: 10.1159/000008243 |
0.383 |
|
| 2000 |
Ogunniyi A, Baiyewu O, Gureje O, Hall KS, Unverzagt F, Siu SH, Gao S, Farlow M, Oluwole OSA, Komolafe O, Hendrie HC. Epidemiology of dementia in Nigeria: Results from the Indianapolis-Ibadan study European Journal of Neurology. 7: 485-490. PMID 11054131 DOI: 10.1046/J.1468-1331.2000.00124.X |
0.394 |
|
| 2000 |
Du Y, Dodel RC, Eastwood BJ, Bales KR, Gao F, Lohmüller F, Müller U, Kurz A, Zimmer R, Evans RM, Hake A, Gasser T, Oertel WH, Griffin WS, Paul SM, ... Farlow MR, et al. Association of an interleukin 1 alpha polymorphism with Alzheimer's disease. Neurology. 55: 480-3. PMID 10953177 DOI: 10.1212/Wnl.55.4.480 |
0.309 |
|
| 2000 |
Vidal R, Calero M, Piccardo P, Farlow MR, Unverzagt FW, Méndez E, Jiménez-Huete A, Beavis R, Gallo G, Gomez-Tortosa E, Ghiso J, Hyman BT, Frangione B, Ghetti B. Senile dementia associated with amyloid beta protein angiopathy and tau perivascular pathology but not neuritic plaques in patients homozygous for the APOE-epsilon4 allele. Acta Neuropathologica. 100: 1-12. PMID 10912914 DOI: 10.1007/S004010051186 |
0.397 |
|
| 2000 |
Murrell JR, Hake AM, Quaid KA, Farlow MR, Ghetti B. Early-onset Alzheimer disease caused by a new mutation (V717L) in the amyloid precursor protein gene. Archives of Neurology. 57: 885-7. PMID 10867787 DOI: 10.1001/Archneur.57.6.885 |
0.391 |
|
| 2000 |
Farlow MR, Cyrus PA. Metrifonate therapy in Alzheimer's disease: a pooled analysis of four randomized, double-blind, placebo-controlled trials. Dementia and Geriatric Cognitive Disorders. 11: 202-11. PMID 10867446 DOI: 10.1159/000017238 |
0.423 |
|
| 2000 |
Lahiri DK, Ge YW, Farlow MR. Effect of a memory-enhancing drug, AIT-082, on the level of synaptophysin. Annals of the New York Academy of Sciences. 903: 387-93. PMID 10818529 DOI: 10.1111/J.1749-6632.2000.Tb06390.X |
0.304 |
|
| 2000 |
Dodel RC, Du Y, Bales KR, Gao F, Eastwood B, Glazier B, Zimmer R, Cordell B, Hake A, Evans R, Gallagher-Thompson D, Thompson LW, Tinklenberg JR, Pfefferbaum A, Sullivan EV, ... ... Farlow MR, et al. Alpha2 macroglobulin and the risk of Alzheimer's disease. Neurology. 54: 438-42. PMID 10668709 DOI: 10.1212/Wnl.54.2.438 |
0.358 |
|
| 2000 |
Evans RM, Emsley CL, Gao S, Sahota A, Hall KS, Farlow MR, Hendrie H. Serum cholesterol, APOE genotype, and the risk of Alzheimer's disease: a population-based study of African Americans. Neurology. 54: 240-2. PMID 10636159 DOI: 10.1212/Wnl.54.1.240 |
0.332 |
|
| 2000 |
McAuley DF, Johnston GD, Marra C, Silveri MC, Gainotti G, Ólafsdóttir M, Skoog I, Marcusson J, Armstrong RA, Cairns NJ, Lantos PL, McGleenon BM, Passmore AP, Eckert GP, Maras A, ... ... Farlow MR, et al. APOE Genotype and Alzheimer´s Disease Dementia and Geriatric Cognitive Disorders. 11: 237-237. DOI: 10.1159/000017243 |
0.351 |
|
| 2000 |
Quaid KA, Murrell JR, Hake AM, Farlow MR, Ghetti B. Presymptomatic genetic testing with an APP mutation in Early-onset Alzheimer disease: A descriptive study of sibship dynamics Journal of Genetic Counseling. 9: 327-341. DOI: 10.1023/A:1009406229745 |
0.41 |
|
| 2000 |
Farlow M, Messina J, Anand R, Hartman R, Veach J. Attenuation in the progression of cognitive deterioration in alzheimer's disease with rivastigmine: A dose-dependent effect Cns Spectrums. 5: 21-22. DOI: 10.1017/S109285290000701X |
0.415 |
|
| 2000 |
Farlow MR, Murrell JR, Hulette CM, Ghetti B. Hereditary lateral sclerosis and Alzheimer disease associated with mutation at codon 261 of the presenilin 1 (PS1) gene Neurobiology of Aging. 21: 62. DOI: 10.1016/S0197-4580(00)82502-6 |
0.36 |
|
| 2000 |
Hake AM, Murrell JR, Unverzagt FW, Ghetti B, Farlow MR. Clinical characteristics in a family with early-onset Alzheimer disease caused by a mutation (V717L) in the APP gene Neurobiology of Aging. 21: 59. DOI: 10.1016/S0197-4580(00)82488-4 |
0.367 |
|
| 1999 |
Farlow MR, Cyrus PA, Nadel A, Lahiri DK, Brashear A, Gulanski B. Metrifonate treatment of AD: influence of APOE genotype. Neurology. 53: 2010-6. PMID 10599773 DOI: 10.1212/Wnl.53.9.2010 |
0.35 |
|
| 1999 |
Kramer PL, Mineta M, Klein C, Schilling K, de Leon D, Farlow MR, Breakefield XO, Bressman SB, Dobyns WB, Ozelius LJ, Brashear A. Rapid-onset dystonia-parkinsonism: linkage to chromosome 19q13. Annals of Neurology. 46: 176-82. PMID 10443882 DOI: 10.1002/1531-8249(199908)46:2<176::Aid-Ana6>3.0.Co;2-2 |
0.325 |
|
| 1999 |
Dodel RC, Bales KR, Farlow MR, Gasser T, Paul SM, Du Y. Rapid Detection of a Pentanucleotide Deletion Polymorphism in the Human α2-Macroglobulin Gene Clinical Chemistry. 45: 307-317. DOI: 10.1093/Clinchem/45.2.307 |
0.328 |
|
| 1999 |
Farlow MR, Cyrus PA. Metrifonate improves the cognitive deficits of patients with Alzheimer's disease relative to placebo treatment and to baseline performance Annals of Long-Term Care. 7: 328-333. |
0.305 |
|
| 1998 |
Qizilbash N, Whitehead A, Higgins J, Wilcock G, Schneider L, Farlow M. Cholinesterase Inhibition for Alzheimer Disease: A Meta-analysis of the Tacrine Trials Jama. 280: 1777-1782. PMID 9842955 DOI: 10.1001/Jama.280.20.1777 |
0.369 |
|
| 1998 |
Farlow MR. New treatments in Alzheimer disease and the continued need for placebo-controlled trials. Archives of Neurology. 55: 1396-8. PMID 9823820 DOI: 10.1001/Archneur.55.11.1396 |
0.365 |
|
| 1998 |
Lahiri DK, Farlow MR, Sambamurti K. The secretion of amyloid beta-peptides is inhibited in the tacrine-treated human neuroblastoma cells. Brain Research. Molecular Brain Research. 62: 131-40. PMID 9813282 DOI: 10.1016/S0169-328X(98)00236-8 |
0.355 |
|
| 1998 |
Farlow MR. Etiology and pathogenesis of Alzheimer's disease. American Journal of Health-System Pharmacy : Ajhp : Official Journal of the American Society of Health-System Pharmacists. 55: S5-10. PMID 9809105 |
0.314 |
|
| 1998 |
Spillantini MG, Murrell JR, Goedert M, Farlow MR, Klug A, Ghetti B. Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. Proceedings of the National Academy of Sciences of the United States of America. 95: 7737-41. PMID 9636220 DOI: 10.1073/Pnas.95.13.7737 |
0.357 |
|
| 1998 |
Farlow MR, Lahiri DK, Poirier J, Davignon J, Schneider L, Hui SL. Treatment outcome of tacrine therapy depends on apolipoprotein genotype and gender of the subjects with Alzheimer's disease. Neurology. 50: 669-77. PMID 9521254 DOI: 10.1212/Wnl.50.3.669 |
0.426 |
|
| 1998 |
Unverzagt FW, Hui SL, Farlow MR, Hall KS, Hendrie HC. Cognitive decline and education in mild dementia. Neurology. 50: 181-5. PMID 9443477 DOI: 10.1212/Wnl.50.1.181 |
0.334 |
|
| 1998 |
Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology. 50: 136-45. PMID 9443470 DOI: 10.1212/Wnl.50.1.136 |
0.378 |
|
| 1998 |
Brashear A, Unverzagt FW, Kuhn ER, Glazier BS, Farlow MR, Perkins AJ, Hui SL. Impaired traffic sign recognition in drivers with dementia American Journal of Alzheimer's Disease. 13: 131-137. DOI: 10.1177/153331759801300305 |
0.311 |
|
| 1997 |
Lahiri DK, Farlow MR, Sambamurti K, Nall C. The effect of tacrine and leupeptin on the secretion of the beta-amyloid precursor protein in HeLa cells. Life Sciences. 61: 1985-92. PMID 9366505 DOI: 10.1016/S0024-3205(97)00868-0 |
0.332 |
|
| 1997 |
Murrell JR, Koller D, Foroud T, Goedert M, Spillantini MG, Edenberg HJ, Farlow MR, Ghetti B. Familial multiple-system tauopathy with presenile dementia is localized to chromosome 17. American Journal of Human Genetics. 61: 1131-8. PMID 9345089 DOI: 10.1086/301594 |
0.333 |
|
| 1997 |
Schneider LS, Farlow MR, Pogoda JM. Potential role for estrogen replacement in the treatment of Alzheimer's dementia. The American Journal of Medicine. 103: 46S-50S. PMID 9344406 DOI: 10.1016/S0002-9343(97)00257-X |
0.373 |
|
| 1997 |
Lahiri DK, Farlow MR, Nurnberger JI, Greig NH. Effects of cholinesterase inhibitors on the secretion of beta-amyloid precursor protein in cell cultures. Annals of the New York Academy of Sciences. 826: 416-21. PMID 9329715 DOI: 10.1111/J.1749-6632.1997.Tb48495.X |
0.315 |
|
| 1997 |
Schneider LS, Farlow M. Combined tacrine and estrogen replacement therapy in patients with Alzheimer's disease. Annals of the New York Academy of Sciences. 826: 317-22. PMID 9329702 DOI: 10.1111/J.1749-6632.1997.Tb48482.X |
0.347 |
|
| 1997 |
Farlow MR. Alzheimer's disease: clinical implications of the apolipoprotein E genotype. Neurology. 48: S30-4. PMID 9153158 DOI: 10.1212/Wnl.48.5_Suppl_6.30S |
0.415 |
|
| 1997 |
Unverzagt FW, Farlow MR, Norton J, Dlouhy SR, Young K, Ghetti B. Neuropsychological function in patients with Gerstmann-Sträussler-Scheinker disease from the Indiana kindred (F198S). Journal of the International Neuropsychological Society : Jins. 3: 169-78. PMID 9126858 DOI: 10.1017/S1355617797001690 |
0.352 |
|
| 1997 |
Spillantini MG, Goedert M, Crowther RA, Murrell JR, Farlow MR, Ghetti B. Familial multiple system tauopathy with presenile dementia: a disease with abundant neuronal and glial tau filaments. Proceedings of the National Academy of Sciences of the United States of America. 94: 4113-8. PMID 9108114 DOI: 10.1073/Pnas.94.8.4113 |
0.391 |
|
| 1996 |
Farlow MR, Lahiri DK, Poirier J, Davignon J, Hui S. Apolipoprotein E genotype and gender influence response to tacrine therapy. Annals of the New York Academy of Sciences. 802: 101-10. PMID 8993489 DOI: 10.1111/J.1749-6632.1996.Tb32603.X |
0.405 |
|
| 1996 |
Piccardo P, Seiler C, Dlouhy SR, Young K, Farlow MR, Prelli F, Frangione B, Bugiani O, Tagliavini F, Ghetti B. Proteinase-K-resistant prion protein isoforms in Gerstmann-Sträussler-Scheinker disease (Indiana kindred). Journal of Neuropathology and Experimental Neurology. 55: 1157-63. PMID 8939199 DOI: 10.1097/00005072-199611000-00007 |
0.347 |
|
| 1996 |
Ghetti B, Piccardo P, Frangione B, Bugiani O, Giaccone G, Young K, Prelli F, Farlow MR, Dlouhy SR, Tagliavini F. Prion protein amyloidosis. Brain Pathology (Zurich, Switzerland). 6: 127-45. PMID 8737929 DOI: 10.1111/J.1750-3639.1996.Tb00796.X |
0.369 |
|
| 1996 |
Parchi P, Castellani R, Capellari S, Ghetti B, Young K, Chen SG, Farlow M, Dickson DW, Sima AA, Trojanowski JQ, Petersen RB, Gambetti P. Molecular basis of phenotypic variability in sporadic Creutzfeldt-Jakob disease. Annals of Neurology. 39: 767-78. PMID 8651649 DOI: 10.1002/Ana.410390613 |
0.319 |
|
| 1996 |
Schneider LS, Farlow MR, Henderson VW, Pogoda JM. Effects of estrogen replacement therapy on response to tacrine in patients with Alzheimer's disease. Neurology. 46: 1580-4. PMID 8649552 DOI: 10.1212/Wnl.46.6.1580 |
0.41 |
|
| 1996 |
Ghetti B, Farlow MR, Crowther RA, Goedert M, Spillantini MG. HEREDITARY MULTIPLE SYSTEM DEGENERATION WITH PRESENILE DEMENTIA Journal of Neuropathology and Experimental Neurology. 55: 608. DOI: 10.1097/00005072-199605000-00026 |
0.351 |
|
| 1996 |
Ghetti B, Piccardo P, Frangione B, Bugiani O, Giaccone G, Young K, Prelli F, Farlow MR, Dlouhy SR, Tagliavini F. Prion protein hereditary amyloidosis: Parenchymal and vascular Seminars in Virology. 7: 189-200. DOI: 10.1006/Smvy.1996.0024 |
0.348 |
|
| 1995 |
Poirier J, Delisle MC, Quirion R, Aubert I, Farlow M, Lahiri D, Hui S, Bertrand P, Nalbantoglu J, Gilfix BM, Gauthier S. Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease. Proceedings of the National Academy of Sciences of the United States of America. 92: 12260-4. PMID 8618881 DOI: 10.1073/Pnas.92.26.12260 |
0.411 |
|
| 1995 |
Hendrie HC, Hall KS, Hui S, Unverzagt FW, Yu CE, Lahiri DK, Sahota A, Farlow M, Musick B, Class CA. Apolipoprotein E genotypes and Alzheimer's disease in a community study of elderly African Americans. Annals of Neurology. 37: 118-20. PMID 7818244 DOI: 10.1002/Ana.410370123 |
0.382 |
|
| 1995 |
Ghetti B, Dlouhy SR, Giaccone G, Bugiani O, Frangione B, Farlow MR, Tagliavini F. Gerstmann-Sträussler-Scheinker disease and the Indiana kindred. Brain Pathology (Zurich, Switzerland). 5: 61-75. PMID 7767492 DOI: 10.1111/J.1750-3639.1995.Tb00578.X |
0.346 |
|
| 1995 |
Schneider LS, Farlow MR. Predicting Response to Cholinesterase Inhibitors in Alzheimerʼs Disease Cns Drugs. 4: 114-124. DOI: 10.2165/00023210-199504020-00004 |
0.335 |
|
| 1994 |
Baldereschi M, Amato MP, Nencini P, Pracucci G, Lippi A, Amaducci L, Gauthier S, Beatty L, Quiroga P, Klassen G, Galea A, Muscat P, Osuntokun B, Ogunniyi A, Portera-Sanchez A, ... ... Farlow M, et al. Cross–national interrater agreement on the clinical diagnostic criteria for dementia Neurology. 44: 239-242. PMID 8309565 DOI: 10.1212/Wnl.44.2.239 |
0.391 |
|
| 1994 |
Farlow M, Murrell J, Ghetti B, Unverzagt F, Zeldenrust S, Benson M. Clinical characteristics in a kindred with early-onset Alzheimer's disease and their linkage to a G-->T change at position 2149 of the amyloid precursor protein gene. Neurology. 44: 105-11. PMID 8290042 DOI: 10.1212/Wnl.44.1.105 |
0.445 |
|
| 1994 |
Farlow M, Ghetti B, Dlouhy S, Giaccone G, Bugiani O, Tagliavini F, Wagner S. Cerebrospinal fluid levels of amyloid beta-protein precursor are low in Gerstmann-Sträussler-Scheinker disease, Indiana kindred. Neurology. 44: 1508-10. PMID 8058158 DOI: 10.1212/Wnl.44.8.1508 |
0.312 |
|
| 1994 |
Wagner SL, Peskind ER, Nochlin D, Provow S, Farrow JS, Pandian MR, Cleveland M, Ito RK, Farlow MR. Decreased levels of soluble amyloid beta-protein precursor are associated with Alzheimer's disease in concordant and discordant monozygous twin pairs. Annals of Neurology. 36: 215-20. PMID 8053657 DOI: 10.1002/Ana.410360214 |
0.365 |
|
| 1994 |
Lahiri DK, Lewis S, Farlow MR. Tacrine alters the secretion of the beta-amyloid precursor protein in cell lines. Journal of Neuroscience Research. 37: 777-87. PMID 8046778 DOI: 10.1002/Jnr.490370612 |
0.352 |
|
| 1994 |
Tagliavini F, Prelli F, Porro M, Rossi G, Giaccone G, Farlow MR, Dlouhy SR, Ghetti B, Bugiani O, Frangione B. Amyloid fibrils in Gerstmann-Sträussler-Scheinker disease (Indiana and Swedish kindreds) express only PrP peptides encoded by the mutant allele. Cell. 79: 695-703. PMID 7954833 DOI: 10.1016/0092-8674(94)90554-1 |
0.332 |
|
| 1994 |
Farlow MR. Management of Alzheimer Disease: Today??s Options and Tomorrow??s Opportunities Alzheimer Disease & Associated Disorders. 8. DOI: 10.1097/00002093-199424000-00006 |
0.358 |
|
| 1994 |
Bugiani O, Giaccone G, Frigerio L, Farlow M, Ghetti B, Tagliavini F. Apolipoprotein E and J immunoreactivity in Gerstmann-Sträussler-Scheinker disease Neurobiology of Aging. 15: S156-S157. DOI: 10.1016/0197-4580(94)93095-3 |
0.301 |
|
| 1994 |
Farlow M, Hershey LA, Sadowsky CH, Gracon SI, Lewis KW, Dolan-Ureno J. Tacrine for Alzheimer's Disease-Reply Jama. 272: 2849-2850. DOI: 10.1001/Jama.1993.03500220034020 |
0.379 |
|
| 1993 |
Tagliavini F, Giaccone G, Prelli F, Verga L, Porro M, Trojanowski JQ, Farlow MR, Frangione B, Ghetti B, Bugiani O. A68 is a component of paired helical filaments of Gerstmann-Sträussler-Scheinker disease, Indiana kindred. Brain Research. 616: 325-9. PMID 8358624 DOI: 10.1016/0006-8993(93)90226-D |
0.369 |
|
| 1993 |
Liepnieks JJ, Ghetti B, Farlow M, Roses AD, Benson MD. Characterization of amyloid fibril beta-peptide in familial Alzheimer's disease with APP717 mutations. Biochemical and Biophysical Research Communications. 197: 386-92. PMID 8267572 DOI: 10.1006/Bbrc.1993.2491 |
0.311 |
|
| 1993 |
Bugiani O, Giaccone G, Verga L, Pollo B, Frangione B, Farlow MR, Tagliavini F, Ghetti B. Beta PP participates in PrP-amyloid plaques of Gerstmann-Sträussler-Scheinker disease, Indiana kindred. Journal of Neuropathology and Experimental Neurology. 52: 64-70. PMID 8093899 DOI: 10.1097/00005072-199301000-00008 |
0.31 |
|
| 1993 |
Giaccone G, Verga L, Bugiani O, Frangione B, Serban D, Prusiner SB, Farlow MR, Ghetti B, Tagliavini F. Corrections: Prion Protein Preamyloid and Amyloid Deposits in Gerstmann- Straussler-Scheinker Disease, Indiana Kindred Proceedings of the National Academy of Sciences of the United States of America. 90: 362. DOI: 10.1073/Pnas.90.1.362B |
0.347 |
|
| 1992 |
Ghetti B, Murrell J, Benson MD, Farlow MR. Spectrum of amyloid beta-protein immunoreactivity in hereditary Alzheimer disease with a guanine to thymine missense change at position 1924 of the APP gene. Brain Research. 571: 133-9. PMID 1611485 DOI: 10.1016/0006-8993(92)90519-F |
0.406 |
|
| 1992 |
Hsiao K, Dlouhy SR, Farlow MR, Cass C, Da Costa M, Conneally PM, Hodes ME, Ghetti B, Prusiner SB. Mutant prion proteins in Gerstmann-Sträussler-Scheinker disease with neurofibrillary tangles. Nature Genetics. 1: 68-71. PMID 1363810 DOI: 10.1038/Ng0492-68 |
0.353 |
|
| 1992 |
Dlouhy SR, Hsiao K, Farlow MR, Foroud T, Conneally PM, Johnson P, Prusiner SB, Hodes ME, Ghetti B. Linkage of the Indiana kindred of Gerstmann-Sträussler-Scheinker disease to the prion protein gene. Nature Genetics. 1: 64-7. PMID 1363809 DOI: 10.1038/Ng0492-64 |
0.376 |
|
| 1992 |
Giaccone G, Verga L, Bugiani O, Frangione B, Serban D, Prusiner SB, Farlow MR, Ghetti B, Tagliavini F. Prion protein preamyloid and amyloid deposits in Gerstmann-Sträussler-Scheinker disease, Indiana kindred. Proceedings of the National Academy of Sciences of the United States of America. 89: 9349-53. PMID 1357663 DOI: 10.1073/Pnas.89.19.9349 |
0.33 |
|
| 1992 |
Farlow M, Ghetti B, Benson MD, Farrow JS, van Nostrand WE, Wagner SL. Low cerebrospinal-fluid concentrations of soluble amyloid beta-protein precursor in hereditary Alzheimer's disease. Lancet. 340: 453-4. PMID 1354785 DOI: 10.1016/0140-6736(92)91771-Y |
0.422 |
|
| 1992 |
Dlouhy SR, Farlow M, Hsiao K, Foroud T, Johnson P, Conneally PM, Prusiner SB, Hodes ME, Ghetti B. Linkage of the indiana kindred variant of Gerstmann-Sträussler-Scheinker disease to a mutation in the prion protein gene (PRNP)☆ Neurobiology of Aging. 13. DOI: 10.1016/0197-4580(92)90402-J |
0.301 |
|
| 1992 |
Giaccone G, Verga L, Bugiani O, Frangione B, Serban D, Prusiner SB, Farlow MR, Ghetti B, Tagliavini F. Pathology, structural and biochemicalPrion protein preamyloid and amyloid deposits in Gerstmann-Sträussler-Scheinker disease, Indiana kindred☆ Neurobiology of Aging. 13. DOI: 10.1016/0197-4580(92)90282-3 |
0.348 |
|
| 1992 |
Farlow M, Bugiani O, Giaccone G, Tagliavini F, Ghetti B, Dlouhy S. A “presymptomatic” case of Gerstmann-Sträussler-Scheinker disease from the indiana kindred has cerebellar deposits of prion protein amyloid and a mutation in the prion protein gene Neurobiology of Aging. 13: S39. DOI: 10.1016/0197-4580(92)90281-2 |
0.315 |
|
| 1992 |
Farlow M, Gracon SI, Hershey LA, Lewis KW, Sadowsky CH, Dolan-Ureno J. A Controlled Trial of Tacrine in Alzheimer's Disease Jama. 268: 2523-2529. DOI: 10.1001/Jama.1992.03490180055026 |
0.386 |
|
| 1991 |
Murrell J, Farlow M, Ghetti B, Benson MD. A mutation in the amyloid precursor protein associated with hereditary Alzheimer's disease. Science (New York, N.Y.). 254: 97-9. PMID 1925564 DOI: 10.1126/Science.1925564 |
0.411 |
|
| 1990 |
Giaccone G, Tagliavini F, Verga L, Frangione B, Farlow MR, Bugiani O, Ghetti B. Neurofibrillary tangles of the Indiana kindred of Gerstmann-Sträussler-Scheinker disease share antigenic determinants with those of Alzheimer disease. Brain Research. 530: 325-9. PMID 2176119 DOI: 10.1016/0006-8993(90)91304-Y |
0.393 |
|
| 1989 |
Farlow MR, Yee RD, Dlouhy SR, Conneally PM, Azzarelli B, Ghetti B. Gerstmann-Sträussler-Scheinker disease. I. Extending the clinical spectrum. Neurology. 39: 1446-52. PMID 2812321 DOI: 10.1212/Wnl.39.11.1446 |
0.33 |
|
| 1989 |
Ghetti B, Tagliavini F, Masters CL, Beyreuther K, Giaccone G, Verga L, Farlow MR, Conneally PM, Dlouhy SR, Azzarelli B. Gerstmann-Sträussler-Scheinker disease. II. Neurofibrillary tangles and plaques with PrP-amyloid coexist in an affected family. Neurology. 39: 1453-61. PMID 2573006 DOI: 10.1212/Wnl.39.11.1453 |
0.414 |
|
| 1987 |
Hendrie HC, Wellman HN, Hall KS, Farlow MR, Brittain HM, Demyer MK. Single photon emission tomographic brain images in dementia of the Alzheimer type. The American Journal of Psychiatry. 144: 387-8. PMID 3493708 DOI: 10.1176/Ajp.144.3.387 |
0.307 |
|
| 1987 |
Farlow MR, DeMyer W, Dlouhy SR, Hodes ME. X-linked recessive inheritance of ataxia and adult-onset dementia: clinical features and preliminary linkage analysis. Neurology. 37: 602-7. PMID 3470628 DOI: 10.1212/Wnl.37.4.602 |
0.31 |
|
| Show low-probability matches. |
